Patent Application
20170088600
The present invention provides a novel composition of TRAIL-R2 receptor or fragment thereof bound to a ligand in crystalline form and novel ligand binding sites and binding agents of TRAIL receptors. Also provided are methods of designing a compound, protein or peptide or identifying a binding agent and methods of modulating binding of a TRAIL receptor to a ligand comprising use of the novel composition or novel ligand binding sites described herein.
The immune system has evolved to protect against the many pathogens that are encountered throughout the lifetime of an individual. In turn, the selective pressure that is exerted by the immune system has shaped pathogen evolution. This co-evolutionary relationship between host and pathogen is particularly clear for viruses that establish persistent infections, such as human herpesviruses (HHV)1,2. Human cytomegalovirus (HCMV, a β-herpesvirus, HHV-5), is a large double-stranded DNA virus that causes a lifelong, persistent/latent infection in ˜50 80% of the US population, varying with age, geography and socioeconomic status. While HCMV infection is largely asymptomatic in healthy persons, it can induce serious disease in those with naïve or compromised immunity, and the high incidence of congenital infection has spurred a strong initiative for vaccine development3. Primary clinical isolates carry at least 19 additional genes within the UL/b′ genomic region (UL133-151 locus) that have been lost in several commonly used HCMV strains that have been passaged extensively in tissue culture4,5, with several of them targeting signaling by the TNFR superfamily (e.g. UL144 and UL138)6.
The interaction between TNF ligands and their respective TNFRs controls pleiotropic biological responses, including cell differentiation, proliferation and apoptosis7. Both TNF ligands and TNFRs are expressed on T cells and, as such, play important roles in T cell co-stimulation. In addition, TNF superfamily members are crucial in controlling herpesvirus infection by initiating the direct killing of infected cells and by enhancing immune responses8,9. For instance, TRAIL death receptor (TRAIL-DR) regulation of apoptosis is critical for maintaining immune homeostasis during HHV infection. The herpesviruses, however, can block apoptosis, likely facilitating their ability to establish lifelong infection 10,11. Using specific genetic mutants of HCMV UL141 has been recently identified to restrict expression of TRAIL-DR (TRAIL-R1/DR4 and TRAIL-R2/DR5)12. It has been shown that cells infected with an HCMVΔUL141 mutant are more susceptible to killing by TRAIL, and that UL141 is both necessary and sufficient to inhibit expression of both the TRAIL receptors12.
HCMV UL141 is also necessary and sufficient to inhibit cell surface expression of CD155 (PVR, poliovirus receptor; nectin-like molecule 5), a ligand for the NK cell activating receptor DNAM-1 (CD226). DNAM-1 also binds a second ligand, CD112 (nec-2, PRR-2, poliovirusreceptor-related protein 2), and UL141 is required, but not sufficient, to target CD112 for proteasome-mediated degradation. As a consequence, both activating ligands for DNAM-1 are removed from the surface of HCMV infected cells, and NK cell killing of those cells is markedly inhibited13-16. In addition, it has been recently shown that UL141 inhibition of TRAIL DR also contributes to inhibit TRAIL-mediated NK cell killing12.
Despite inducing a strong host immune response, HCMV persists for life in a latent form, which can be rapidly reactivated in the absence of host immunity, highlighting the dynamic relationship between the host and this virus. Characterizing the structural and molecular basis of the interactions that occur between specific HCMV proteins and the host molecules they target is crucial for understanding of viral persistence, and will ultimately facilitate vaccine and antiviral drug development.
The present inventors have discovered the structural and biochemical basis of a novel ligand binding site of a TRAIL receptor.
The present inventors have discovered a novel, non-canonical interaction between UL141 and TRAIL-R2, an interaction that has evolved to inhibit cell death mediated by TRAIL signaling and mute host defenses. Previously, TRAIL (TNFSF10) was the only known ligand for the four TRAIL receptors (TNFRSF10a-d). Remarkably, UL141 displays no structural homology to TNF superfamily ligands, and instead utilizes its Ig-domain to bind with high affinity to the TRAIL death receptor. Without being limited to any particular theory, the UL141 protein encoded by low-passage isolates of human cytomegalovirus (HCMV) may mimic a host molecule that binds the TRAIL death receptors (DR). Thus in one aspect, there is presently provided a composition comprising a TRAIL-R2 receptor or fragment thereof bound to a ligand in crystalline form. In particular embodiments, the ligand is bound to an amino acid sequence of TRAIL-R2 receptor that comprises, consists of or consists essentially of amino acid residues 58-184 of TRAIL-R2 receptor or a subsequence, portion, homologue, variant or derivative thereof. In certain embodiments, the ligand is bound to an amino acid sequence of TRAIL-R2 receptor that comprises, consists of or consists essentially of amino acid residues 58-212 of TRAIL-R2 receptor or a subsequence, portion, homologue, variant or derivative thereof.
In particular embodiments of the composition of the present invention, the crystalline form has unit cell parameters of a=67.74 Å, b=97.01 Å and c=140.94 Å or a=67.71 Å, b=97.67 Å, c=141.31 Å. In further embodiments, the composition comprises the relative structural coordinates set forth in
In certain embodiments of the presently described composition, the TRAIL-R2 receptor has one or more binding patches in contact with the ligand, the binding patches comprising, consisting of or consisting essentially of: amino acid residues E78 and D109 of a TRAIL-R2 receptor; amino acid residue D148 of a TRAIL-R2 receptor; amino acid residues V167, V179 and W173 of a TRAIL-R2 receptor; amino acid residues Y103, N134 and R133 of a TRAIL-R2 receptor; amino acid residues L110, L114 and F112 of a TRAIL-R2 receptor; and amino acid residues E151 and E147 of a TRAIL-R2 receptor; or a subsequence, portion, homologue, variant or derivative thereof.
In particular embodiments of the composition of the present invention, the ligand is UL141.
In another aspect, there is provided an isolated or purified ligand binding site of a TRAIL-R2 receptor, or a subsequence, portion, homologue, variant or derivative thereof. In different embodiments, the isolated or purified ligand binding site or subsequence, portion, homologue, variant or derivative thereof comprises a structure set forth in any one of
In certain embodiments of the present inventions, the isolated or purified ligand binding site or subsequence, portion, homologue, variant or derivative thereof comprises, consists of or consists essentially of amino acid residues 58-184 of TRAIL-R2 receptor or a subsequence, portion, homologue, variant or derivative thereof. In particular embodiments, the isolated or purified ligand binding site or subsequence, portion, homologue, variant or derivative thereof of comprises, consists of or consists essentially of amino acid residues 58-212 of TRAIL-R2 receptor or a subsequence, portion, homologue, variant or derivative thereof.
In certain embodiments, the isolated or purified ligand binding site or subsequence, portion, homologue, variant or derivative thereof comprises, consists of or consists essentially of structural coordinates set forth in
In another aspect, there is presently provided a method of designing a compound, protein or peptide that interacts with a TRAIL-R2 receptor, the method comprising: use of the composition of the present invention to design the compound, protein or peptide, wherein the compound, protein or peptide interacts with a ligand binding site of the TRAIL-R2 receptor, the ligand binding site comprising, consisting of or consisting essentially of amino acid residues 58-184 of the TRAIL-R2 receptor or a subsequence, portion, homologue, variant or derivative thereof; producing or synthesizing the compound, protein or peptide; contacting the compound, protein or peptide with the TRAIL-R2 receptor; and detecting interaction of the compound, protein or peptide with the ligand binding site comprising, consisting of or consisting essentially of amino acid residues 58-184 of the TRAIL-R2 receptor or a subsequence, portion, homologue, variant or derivative thereof.
In a further aspect, there is presently provided a method of identifying a binding agent that interacts with at least one amino acid of a TRAIL-R2 receptor ligand binding site, the method comprising providing a test agent; contacting the test agent with a protein or peptide comprising, consisting of or consisting essentially of amino acid residues 58-184 of the TRAIL-R2 receptor or subsequence, portion, homologue, variant or derivative thereof; and detecting interaction of the test agent with the protein or peptide comprising, consisting of or consisting essentially of amino acid residues 58-184 of TRAIL-R2 receptor or subsequence, portion, homologue, variant or derivative thereof. In particular embodiments, the method comprises contacting the test agent with a protein or peptide comprising, consisting of or consisting essentially of amino acid residues 58-212 of the TRAIL-R2 receptor or subsequence, portion, homologue, variant or derivative thereof; and detecting interaction of the test agent with the protein or peptide comprising, consisting of or consisting essentially of amino acid residues 58-212 of TRAIL-R2 receptor or subsequence, portion, homologue, variant or derivative thereof. In certain embodiments, the method comprises identifying a binding agent that interacts with one or more binding patches of the TRAIL-R2 receptor, the binding patches comprising, consisting of or consisting essentially of: amino acid residues E78 and D109 of a TRAIL-R2 receptor; amino acid residue D148 of the TRAIL-R2 receptor; amino acid residues V167, V179 and W173 of a TRAIL-R2 receptor; amino acid residues Y103, N134 and R133 of aTRAIL-R2 receptor; amino acid residues L110, L114 and F112 of a TRAIL-R2 receptor; and amino acid residues E151 and E147 of the TRAIL-R2 receptor; or a subsequence, portion, homologue, variant or derivative thereof; the method comprising: providing a test agent; contacting the test agent with a protein or peptide comprising, consisting of or consisting essentially of one or more the binding patches of the TRAIL receptor; and detecting interaction of the test agent with the protein or peptide comprising, consisting of or consisting essentially of one or more of the binding patches of the TRAIL receptor.
In particular embodiments of the presently provided method of identifying a binding agent, the binding agent modulates binding of a TRAIL-R2 receptor to a ligand that interacts with at least one amino acid of a TRAIL receptor ligand binding site. In different embodiments, the binding agent is a TRAIL-R2 receptor agonist, a TRAIL-R2 receptor antagonist, an antibody, an inhibitory nucleic acid or a ligand mimetic.
In yet a further aspect, there is presently provided a binding agent that interacts with a TRAIL-R2 receptor, the binding agent interacting with at least one amino acid of a ligand binding site of the TRAIL-R2 receptor, the ligand binding site comprising, consisting of or consisting essentially of amino acid residues 58-184 of TRAIL-R2 receptor or a subsequence, portion, homologue, variant or derivative thereof. In certain embodiments, the ligand binding site comprises, consists of or consists essentially of amino acid residues 58-212 of TRAIL-R2 receptor or a subsequence, portion, homologue, variant or derivative thereof. In particular embodiments, the binding agent of the present invention interacts with one or more binding patches of the TRAIL-R2 receptor, the binding patches comprising, consisting of or consisting essentially of: amino acid residue D148 of a TRAIL-R2 receptor; amino acid residues V167, V179 and W173 of a TRAIL-R2 receptor; amino acid residues Y103, N134 and R133 of a TRAIL-R2 receptor; amino acid residues L110, L114 and F112 of aTRAIL-R2 receptor; and amino acid residues E151 and E147 of a TRAIL-R2 receptor; or a subsequence, portion, homologue, variant or derivative thereof.
In particular embodiments of the present invention, the binding agent modulates binding of the TRAIL-R2 receptor to a ligand that interacts with at least one amino acid of the TRAIL-R2 receptor ligand binding site. In certain embodiments, the binding agent modulates TRAIL-R2 receptor activity. In different embodiments, the binding agent is a TRAIL receptor agonist, a TRAIL receptor antagonist, an antibody, an inhibitory nucleic acid or a ligand mimetic.
In particular embodiments of the present invention, the binding agent modulates an immune response, an anti-inflammatory response, cell proliferation or an apoptotic response mediated by the TRAIL-R2 receptor or a ligand thereof.
In another aspect of the present invention, there is provided a method for modulating binding of a TRAIL-R2 receptor to a ligand, the method comprising contacting the TRAIL-R2 receptor with a binding agent or ligand, or an agonist or antagonist thereof, that interacts with at least one amino acid of a ligand binding site of the TRAIL-R2 receptor, the ligand binding site comprising, consisting of or consisting essentially of amino acid residues 58-184 of TRAIL-R2 receptor or a subsequence, portion, homologue, variant or derivative thereof. In particular embodiments, the ligand binding site comprises, consists of or consists essentially of amino acid residues 58-212 of TRAIL-R2 receptor or a subsequence, portion, homologue, variant or derivative thereof.
In certain embodiments of the presently provided method for modulating binding of a TRAIL-R2 receptor to a ligand, the method comprises modulating the activity of a TRAIL-R2 receptor. In different embodiments, the method comprises decreasing, reducing, inhibiting, suppressing, disrupting, eliciting, stimulating, inducing, promoting, increasing or enhancing TRAIL-R2 receptor activity. In certain embodiments, the method comprises modulating an immune response, an anti-inflammatory response, cell proliferation or an apoptotic response mediated by the TRAIL-R2 receptor or a ligand thereof.
Other aspects and features of the present invention will become apparent to those of ordinary skill in the art upon review of the following description of specific embodiments of the invention in conjunction with the accompanying figures.
The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
In the figures, which illustrate, by way of example only, embodiments of the present invention:
In accordance with the present invention, there is provided a novel ligand binding site of a TRAIL receptor, or a subsequence, portion, homologue, variant or derivative thereof. In different embodiments, the novel binding site may be present on a TRAIL-R1, TRAIL-R2, TRAIL-R3 or TRAIL-R4 receptor. In a particular embodiment of the present invention there is provided a novel ligand binding site of a TRAIL-R2 receptor or a subsequence, portion, homologue, variant or derivative thereof.
The present inventors have solved the crystal structure of a TRAIL-R2 receptor bound to a ligand (UL141) and have discovered a novel ligand binding site of a TRAIL-R2 receptor as well as novel ligand binding patches within the novel ligand binding site.
Thus, there is presently provided a novel ligand binding site of a TRAIL-R2 receptor or a subsequence, portion, homologue, variant or derivative thereof, comprising relative structural coordinates set forth in
In particular embodiments of the present invention, the ligand binding site, or subsequence, portion, homologue, variant or derivative thereof, described herein comprises, consists or consists essentially of amino acid residues 58-184 of TRAIL-R2 receptor or a subsequence, portion, homologue, variant or derivative thereof. In certain embodiments
In particular embodiments, the ligand binding site, or subsequence, portion, homologue, variant or derivative thereof, comprises one or more novel binding patches. In different embodiments, the binding patches may comprise, consist of or consist essentially of one or more of amino acid residues E78 and D109 of TRAIL-R2 receptor; amino acid residue D148 of TRAIL-R2 receptor; amino acid residues V167, V179 and W173 of TRAIL-R2 receptor; amino acid residues Y103, N134 and R133 of TRAIL-R2 receptor; amino acid residues L110, L114 and F112 of TRAIL-R2 receptor and amino acid residues E151 and E147 of TRAIL-R2 receptor, or a subsequence, portion, homologue, variant or derivative thereof.
As used herein, the terms “bind” or “binding” refers to any interaction between two molecules, whether direct or indirect or whether functional or physical. Thus, the term binding may refer to a physical interaction at the molecular level or functional interaction that need not require physical interaction or binding. A ligand or binding agent that binds a TRAIL receptor may partially or completely inhibit, decrease or reduce a physical interaction or a functional interaction between a TRAIL receptor and another ligand or binding agent Inhibition of binding can be due to steric hindrance, occupation, blocking or modification or alteration of the site of physical or functional interaction, or alteration of a modification or another factor that participates in binding between the TRAIL receptor and a ligand or binding agent.
Binding and interaction as used herein includes both cis and trans binding or interaction. As used herein, a “cis” interaction or binding refers to interaction/binding of two entities (e.g., proteins) expressed on the same cell. A “trans” interaction or binding refers to interaction/binding between proteins expressed on distinct cells (i.e., two different cells). Such cis and trans interactions between two entities can involve a direct interaction/binding. Alternatively, such cis and trans interactions between two entities can also be mediated by an intermediary molecule and need not involve direct interaction/binding between the two entities. For example, a “trans” interaction between two cells can occur when a ligand of a TRAIL receptor expressed on a cell binds to a TRAIL receptor expressed on a different cell or when a soluble ligand of a TRAIL receptor binds to a TRAIL receptor on one cell to link the TRAIL receptor to another molecule expressed on a different cell. Thus, a novel ligand of a TRAIL receptor as described herein can function as an intermediary that mediates the interaction/binding of a TRAIL receptor to other molecules on the same cell or on another cell. A novel ligand of a TRAIL receptor as described herein may also function to aggregate cells or molecules on different cells.
As used herein, a “ligand binding site” is a portion of one or more proteins or peptides that binds a ligand. Binding sites can vary in size, for example, from one amino acid up to a polypeptide that is one amino acid less than the entire length of the full-length protein containing the ligand binding site. As will be understood by a person of skill in the art, a ligand binding site may comprise contiguous amino acids or may comprise two or more non-contiguous amino acids of a TRAIL receptor, the amino acids of a ligand binding sited being separated by one or more amino acid residues. In certain embodiments, a ligand binding site may comprise contiguous and non-contiguous amino acids. In particular embodiments, the ligand binding site of the present invention comprises one or more continguous or non-contiguous amino acids of amino acid residues 58 to 212 of a TRAIL-R2 receptor or a subsequence, portion, homologue, variant or derivative thereof. In certain embodiments, the ligand binding site comprises one or more amino acids of amino acid residues 58 to 184 of a TRAIL-R2 receptor or a subsequence, portion, homologue, variant or derivative thereof. In certain embodiments, the ligand binding site comprises one or more amino acids of amino acid residues 185 to 212 of a TRAIL-R2 receptor or a subsequence, portion, homologue, variant or derivative thereof. Thus in different embodiments, the ligand binding site comprises one or more amino acids of amino acid residues 58 to 185, 58 to 186, 58 to 187, 58 to 188, 58 to 189, 58 to 190, 58 to 191, 58 to 192, 58 to 193, 58 to 194, 58 to 195, 58 to 196, 58 to 197, 58 to 198, 58 to 199, 58 to 200, 58 to 201, 58 to 202, 58 to 203, 58 to 204, 58 to 205, 58 to 206, 58 to 207, 58 to 208, 58 to 209, 58 to 210, 58 to 211 or 58 to 212 of TRAIL-R2 receptor or a subsequence, portion, homologue, variant or derivative thereof. In certain embodiments, the ligand binding site comprises one or more amino acids of amino acid residues 58 to 184 and one or more amino acids of amino acid residues 185 to 212 of a TRAIL-R2 receptor or a subsequence, portion, homologue, variant or derivative thereof.
As used herein, a “binding patch” refers to one or more amino acids of a ligand binding site that bind one or more amino acids of a ligand. Thus a binding patch of a TRAIL receptor refers to one or more amino acids within a ligand binding site of the TRAIL receptor that bind one or more amino acids of a ligand. As will be understood by a person of skill in the art, a binding patch may comprise contiguous amino acids or may comprise two or more non-contiguous amino acids of a TRAIL receptor binding site, the amino acids of a binding patch being separated by one or more amino acid residues. In certain embodiments, a ligand binding site may comprise contiguous and non-contiguous amino acids. In particular embodiments, a binding patch comprises one or more amino acids of amino acid residues 58-212 of a TRAIL-R2 receptor or a subsequence, portion, homologue, variant or derivative thereof. In further embodiments, a binding patch comprises one or more amino acids of amino acid residues 58-184 of a TRAIL-R2 receptor or a subsequence, portion, homologue, variant or derivative thereof. In certain embodiments, a binding patch comprises one or more amino acids of amino acid residues 185-212 of a TRAIL-R2 receptor or a subsequence, portion, homologue, variant or derivative thereof.
In particular embodiments, the present invention provides a novel ligand binding patch of a TRAIL-R2 receptor comprising, consisting of or consisting essentially of one or more of amino acid residues E78 and D109 of TRAIL-R2 receptor; amino acid residue D148 of TRAIL-R2 receptor; amino acid residues V167, V179 and W173 of TRAIL-R2 receptor; amino acid residues Y103, N134 and R133 of TRAIL-R2 receptor; amino acid residues L110, L114 and F112 of TRAIL-R2 receptor; and amino acid residues E151 and E147 of TRAIL-R2 receptor, or subsequence, portion, homologue, variant or derivative thereof.
Provided in the present invention are homologues of the novel ligand binding site of a TRAIL receptor described herein. In particular embodiments of the present invention, there is provided homologues of the novel ligand binding site of a TRAIL-R2 receptor described herein. In certain embodiments, there is provided a novel ligand binding site of a TRAIL-R1 receptor, TRAIL-R3 receptor or TRAIL-R4 receptor that is homologous to the novel ligand binding site of a TRAIL-R2 receptor described herein. In particular embodiments, there is presently provided a novel ligand binding site of a TRAIL-R1 receptor, TRAIL-R3 receptor or TRAIL-R4 receptor comprising, consisting of or consisting essentially of an amino acids sequence that is homologous to amino acids residues 58-184 of a TRAIL-R2 receptor, or a subsequence, portion, homologue, variant or derivative thereof. In particular embodiments, there is presently provided a novel ligand binding site of a TRAIL-R1 receptor, TRAIL-R3 receptor or TRAIL-R4 receptor comprising, consisting of or consisting essentially of an amino acids sequence that is homologous to amino acids residues 185-212 of a TRAIL-R2 receptor, or a subsequence, portion, homologue, variant or derivative thereof. In certain embodiments of the present invention, a novel ligand binding site of a TRAIL-R1 receptor, TRAIL-R3 receptor or TRAIL-R4 receptor described herein may comprise, consist of or consist essentially of amino acids that are homologous to one or more of amino acid residues E78 and D109 of TRAIL-R2 receptor; amino acid residue D148 of TRAIL-R2 receptor; amino acid residues V167, V179 and W173 of TRAIL-R2 receptor; amino acid residues Y103, N134 and R133 of TRAIL-R2 receptor; amino acid residues L110, L114 and F112 of TRAIL-R2 receptor; and amino acid residues E151 and E147 of TRAIL-R2 receptor.
HCMV is a β-herpesvirus with a dsDNA genome of ˜230 kB, and like all herpesviruses, establishes a lifelong, persistent/latent infection of its host. To accomplish this, HCMV encodes a multitude of ‘immune modulatory’ proteins that target immune pathways and thwart host defenses54. The present inventors had previously identified several viral proteins that target signaling by members of the TNF-TNFR superfamily. A specific example of this is the HCMV UL144 protein55. The present inventors characterized UL144 as an orthologue of HVEM (TNFRSF14) that specifically binds to BTLA. BTLA is an inhibitory receptor that encodes an Ig-domain and restricts activation of T cells (and potentially other immune cells), similar to the CD28-related inhibitory receptors CTLA-4 and PD-1. Strikingly, UL144 is a much more potent inhibitor of T cell proliferation than HVEM56, likely due to refinement of UL144 function resulting from extensive co-evolution between HCMV and its host. Consequently, UL144 only binds to BTLA, and not to LIGHT (homologous to LT, shows inducible expression, competes with HSV glycoprotein D for HVEM, a receptor expressed by T lymphocytes) or CD160, whereas HVEM binds all 3 of these molecules57.
The UL144-BTLA-HVEM signaling network serves as a primary example where a HCMV protein has ‘taught’ about alternate/novel TNFR ligands. Consequently, without being limited to any particular theory, it appears that UL141 is also a structural and/or functional mimic of a novel ligand for TRAIL-R2. Support for this is provided by the several examples of seemingly disparate results that have been observed in mice genetically deficient for either TRAIL or TRAIL-R2, which was also the case for HVEM and LIGHT deficient mice before BTLA was identified to bind HVEM. Further, the present invention provides characterization of the UL141-TRAIL-R2 binding complex by X-ray crystallographic methods which reveals that UL141 uses an Ig-like domain to bind to TRAIL-R2, paralleling how BTLA utilizes an Ig-domain to bind to UL144 and HVEM. In addition, the present inventors have also discovered through structural, biochemical and mutagenesis analysis of the UL141-TRAILR2 complex that UL141 binds to TRAIL-R2 in a fashion distinct from TRAIL, indicating it is not a TRAIL mimic.
Thus novel ligands of a TRAIL receptor, or subsequence, portion, homologue, variant or derivative thereof, of the present invention may bind the novel ligand binding sites of a TRAIL receptor described herein. Thus, in different embodiments, a novel ligand of a TRAIL receptor, or subsequence, portion, homologue, variant or derivative thereof, may bind one or more of a novel ligand binding site of TRAIL-R1, a novel ligand binding site of TRAIL-R2, a novel ligand binding site of TRAIL-R3 and a novel ligand binding site of TRAIL-R4, described herein. The novel ligand may bind one or more TRAIL receptors. In different embodiments, the novel ligand may bind two or more TRAIL receptors substantially contemporaneously or sequentially.
In particular embodiments of the present invention, a novel ligand may bind a protein or peptide comprising, consisting of or consisting essentially of an amino acid sequence of residues 58-184, an amino acid sequence of residues 185-212 or an amino acid sequence of 58 to 212 of a TRAIL-R2 receptor or a subsequence, portion, homologue, variant or derivative thereof. In certain aspects, the novel ligand may bind a novel ligand binding site of a TRAIL-R2 receptor as described herein. In specific embodiments, the novel ligand binds to one or more binding patches of the TRAIL-R2 receptor, the binding patches comprising, consisting of or consisting essentially of amino acid residues E78 and D109 of the TRAIL-R2 receptor; amino acid residue D148 of the TRAIL-R2 receptor; amino acid residues V167, V179 and W173 of the TRAIL-R2 receptor; amino acid residues Y103, N134 and R133 of the TRAIL-R2 receptor; amino acid residues L110, L114 and F112 of the TRAIL-R2 receptor; and amino acid residues E151 and E147 of the TRAIL-R2 receptor.
In some embodiments, the novel ligand of a TRAIL receptor of the present invention comprises a purified natural protein or peptide or a subsequence, portion, homologue, variant or derivative thereof. In certain embodiments, the novel ligand may modulate the activity of the TRAIL receptor, including but not limited to decreasing, reducing, inhibiting, suppressing, disrupting, eliciting, stimulating, inducing, promoting, increasing or enhancing activity of a TRAIL receptor or a ligand thereof. In particular embodiments, the novel ligand decreases, reduces, inhibits, suppresses, disrupts, elicits, stimulates, induces, promotes, increases or enhances an immune response, an anti-inflammatory response, cell proliferation or an apoptotic response mediated by the TRAIL receptor or a ligand thereof.
In certain embodiments of the present invention, the novel ligand of a TRAIL receptor may be homologous in whole or in part to UL141.
As disclosed herein, presently provided novel ligand binding site of a TRAIL receptor or novel ligand of a TRAIL receptor, or subsequence, portion, homologue, variant or derivative thereof, include those having all or at least partial sequence identity to one or more exemplary novel ligand binding sites of a TRAIL receptor or novel ligand of a TRAIL receptor, or a subsequence, portion, homologue, variant or derivative thereof (e.g., the novel ligand binding site of TRAIL-R2 receptor set forth in
The term “identity” and grammatical variations thereof, mean that two or more referenced entities are the same. Thus, where ligand binding sites or ligands, or subsequences, portions or modifications thereof are identical, they have the same amino acid sequence. The identity can be over a defined area (region or domain) of the sequence. As will be understood by a person of skill in the art, areas, regions, amino acids, domains, ligands or binding sites that are “homologous” or “homologues” mean that a portion of two or more referenced entities share homology.
The extent of identity between two ligand binding sites or ligands can be ascertained using a computer program and mathematical algorithm known in the art. Such algorithms that calculate percent sequence identity (homology) generally account for sequence gaps and mismatches over the comparison region or area. For example, a BLAST (e.g., BLAST 2.0) search algorithm (see, e.g., Altschul et al., J. Mol. Biol. 215:403 (1990), publicly available through NCBI) has exemplary search parameters as follows: Mismatch-2; gap open 5; gap extension 2. For polypeptide sequence comparisons, a BLASTP algorithm is typically used in combination with a scoring matrix, such as PAM100, PAM 250, BLOSUM 62 or BLOSUM 50. FASTA (e.g., FASTA2 and FASTA3) and SSEARCH sequence comparison programs are also used to quantitate the extent of identity (Pearson et al., Proc. Natl. Acad. Sci. USA 85:2444 (1988); Pearson, Methods Mol Biol. 132:185 (2000); and Smith et al., J. Mol. Biol. 147:195 (1981)). Programs for quantitating protein structural similarity using Delaunay-based topological mapping have also been developed (Bostick et al., Biochem Biophys Res Commun. 304:320 (2003)).
In accordance with the invention, modified, derivative and variant forms of the presently described novel ligand binding sites of a TRAIL receptor or novel ligands of a TRAIL receptor, or subsequences or portions thereof are provided. Such forms, referred to as “modifications” or “variants” and grammatical variations thereof, are a novel ligand binding site of a TRAIL receptor or a novel ligand of a TRAIL receptor, or subsequence or portion thereof, that deviates from a reference sequence, such as the sequences for TRAIL receptors provided herein. Such modifications may have greater or less activity or function than a reference novel ligand binding site of a TRAIL receptor or novel ligand of a TRAIL receptor, or subsequence or portion thereof, such as the ability to decrease, reduce, inhibit, suppress, disrupt, elicit, stimulate, induce, promote, increase or enhance TRAIL receptor activity including but not limited to an immune response, an anti-inflammatory response, cell proliferation or an apoptotic response mediated by the TRAIL receptor or a ligand thereof. Thus, novel ligand binding sites of a TRAIL receptor or novel ligands of a TRAIL receptor, or subsequences or portions thereof include a ligand binding site of a TRAIL receptor or a novel ligand of a TRAIL receptor having substantially the same, greater or less relative activity or function as a reference novel ligand binding site of a TRAIL receptor or a novel ligand of a TRAIL receptor, in vitro or in vivo.
Non-limiting examples of modifications include one or more amino acid substitutions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1, 12, 13, 14, 15, 16, 17, 18, 19, 20, 20-25, 25-30, 30-50, 50-100, or more residues), additions and insertions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1, 12, 13, 14, 15, 16, 17, 18, 19, 20, 20-25, 25-30, 30-50, 50-100, or more residues) and deletions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1, 12, 13, 14, 15, 16, 17, 18, 19, 20, 20-25, 25-30, 30-50, 50-100) of a reference novel ligand binding site of a TRAIL receptor or novel ligand of a TRAIL receptor, or subsequence or portion thereof.
Specific non-limiting examples of substitutions include conservative and non-conservative amino acid substitutions. A “conservative substitution” is the replacement of one amino acid by a biologically, chemically or structurally similar residue. Biologically similar means that the substitution does not destroy a biological activity. Structurally similar means that the amino acids have side chains with similar length, such as alanine, glycine and serine, or a similar size. Chemical similarity means that the residues have the same charge, or are both hydrophilic or hydrophobic. Particular examples include the substitution of one hydrophobic residue, such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another, such as the substitution of arginine for lysine, glutamic for aspartic acids, or glutamine for asparagine, serine for threonine, and the like.
An addition can be the covalent or non-covalent attachment of any type of molecule to the sequence. Specific examples of additions include glycosylation, acetylation, phosphorylation, amidation, formylation, ubiquitination, and derivatization by protecting/blocking groups and any of numerous chemical modifications. Additional specific non-limiting examples of an addition are one or more additional amino acid residues. Accordingly, a novel ligand binding site of a TRAIL receptor or a novel ligand of a TRAIL receptor, or a subsequence, portion, homologue, variant or derivative thereof, as described herein can be a part of or contained within a larger molecule, such as another protein or peptide sequence, such as a fusion or chimera with a different novel ligand binding site of a TRAIL receptor or novel ligand of a TRAIL receptor, or a subsequence, portion, homologue, variant or derivative thereof, or a non-novel ligand binding site of a TRAIL receptor or a novel ligand of a TRAIL receptor, or a subsequence, portion, homologue, variant or derivative thereof. In particular embodiments, an addition is a fusion (chimeric) sequence, an amino acid sequence having one or more molecules not normally present in a reference native (wild type) sequence covalently attached to the sequence.
The term “chimeric” and grammatical variations thereof, when used in reference to a sequence, means that the sequence contains one or more portions that are derived from, obtained or isolated from, or based upon other physical or chemical entities. For example, a chimera of two or more different proteins may have one part a novel ligand binding site of a TRAIL receptor or a novel ligand of a TRAIL receptor, or a subsequence, portion, homologue, variant or derivative thereof, and a second part of the chimera may be from a different novel ligand binding site of a TRAIL receptor or novel ligand of a TRAIL receptor, or a may not be from a novel ligand binding site of a TRAIL receptor or a novel ligand of a TRAIL receptor.
Another particular example of a modified sequence having an amino acid addition is one in which a second heterologous sequence, i.e., heterologous functional domain is attached (covalent or non-covalent binding) that confers a distinct or complementary function. Heterologous functional domains are not restricted to amino acid residues. Thus, a heterologous functional domain can consist of any of a variety of different types of small or large functional moieties. Such moieties include nucleic acid, peptide, carbohydrate, lipid or small organic compounds, such as a drug (e.g., an antiviral), a metal (gold, silver), and radioisotope. Thus, in other embodiments, there is presently provided a novel ligand binding site of a TRAIL receptor or a novel ligand of a TRAIL receptor, or a subsequence, portion, homologue, variant or derivative thereof, wherein the heterologous functional domain confers a distinct function, on the novel ligand binding site of a TRAIL receptor or novel ligand of a TRAIL receptor, or a subsequence, portion, homologue, variant or derivative thereof. Such constructs containing a novel ligand binding site of a TRAIL receptor or a novel ligand of a TRAIL receptor, or a subsequence, portion, homologue, variant or derivative thereof, and a heterologous domain are also referred to as chimeras.
Linkers, such as amino acid or peptidomimetic sequences may be inserted between the sequence and the addition (e.g., heterologous functional domain) so that the two entities maintain, at least in part, a distinct function or activity. Linkers may have one or more properties that include a flexible conformation, an inability to form an ordered secondary structure or a hydrophobic or charged character, which could promote or interact with either domain. Amino acids typically found in flexible protein regions include Gly, Asn and Ser. Other near neutral amino acids, such as Thr and Ala, may also be used in the linker sequence. The length of the linker sequence may vary without significantly affecting a function or activity of the fusion protein (see, e.g., U.S. Pat. No. 6,087,329). Linkers further include chemical moieties and conjugating agents, such as sulfo-succinimidyl derivatives (sulfo-SMCC, sulfo-SMPB), disuccinimidyl suberate (DSS), disuccinimidyl glutarate (DSG) and disuccinimidyl tartrate (DST).
Further non-limiting examples of additions are detectable labels. Thus, in another embodiment, the invention provides a novel ligand binding site of a TRAIL receptor or a novel ligand of a TRAIL receptor, or a subsequence, portion, homologue, variant or derivative thereof, that is detectably labeled. Specific examples of detectable labels include fluorophores, chromophores, radioactive isotopes (e.g., S35, P32, I125), electron-dense reagents, enzymes, ligands and receptors. Enzymes are typically detected by their activity. For example, horseradish peroxidase is usually detected by its ability to convert a substrate such as 3,3-′,5,5-′-tetramethylbenzidine (TMB) to a blue pigment, which can be quantified.
Another non-limiting example of an addition is an insertion of an amino acid within any novel ligand binding site of a TRAIL receptor or a novel ligand of a TRAIL receptor, or a subsequence, portion, homologue, variant or derivative thereof. In particular embodiments, an insertion is of one or more amino acid residues inserted into the amino acid sequence of a novel ligand binding site of a TRAIL receptor or a novel ligand of a TRAIL receptor, or a subsequence, portion, homologue, variant or derivative thereof,
Modified and variant novel ligand binding sites of a TRAIL receptor or novel ligands of a TRAIL receptor, or a subsequence, portion, homologue, variant or derivative thereof, also include one or more D-amino acids substituted for L-amino acids (and mixtures thereof), structural and functional analogues, for example, peptidomimetics having synthetic or non-natural amino acids or amino acid analogues and derivatized forms. Modifications include cyclic structures such as an end-to-end amide bond between the amino and carboxy-terminus of the molecule or intra- or inter-molecular disulfide bond. Novel ligand binding sites of a TRAIL receptor or novel ligands of a TRAIL receptor, or a subsequence, portion, homologue, variant or derivative thereof, may be modified in vitro or in vivo, e.g., post-translationally modified to include, for example, sugar residues, phosphate groups, ubiquitin, fatty acids, lipids, etc.
Specific non-limiting examples of a novel ligand binding site of a TRAIL receptor or a novel ligand of a TRAIL receptor, or a subsequence, portion, homologue, variant or derivative thereof, include an amino acid sequence comprising at least one amino acid deletion from a full length amino acid sequence of a novel ligand binding site of a TRAIL receptor or a novel ligand of a TRAIL receptor, or a homologue, variant or derivative thereof. In particular embodiments, a protein subsequence or portion is from about 2 to 127 amino acids in length, provided that said subsequence or portion is at least one amino acid less in length than the full-length sequence of the novel ligand binding site of a TRAIL receptor or novel ligand of a TRAIL receptor, or a homologue, variant or derivative thereof. In additional particular embodiments, a protein subsequence or portion is from about 2 to 5, 5 to 10, 10 to 15, 15 to 20, 20 to 25, 25 to 50, 50 to 100, 100 to 125 or 125 to 127 amino acids in length, provided that said subsequence or portion is at least one amino acid less in length than the full-length sequence of a novel ligand binding site of a TRAIL receptor or novel ligand of a TRAIL receptor, or a homologue, variant or derivative thereof.
Novel ligand binding sites of a TRAIL receptor or novel ligands of a TRAIL receptor, or a subsequence, portion, homologue, variant or derivative thereof, can be produced by any of a variety of standard protein purification or recombinant expression techniques. For example, a novel ligand binding site of a TRAIL receptor or a novel ligand of a TRAIL receptor, or a subsequence, portion, homologue, variant or derivative thereof, can be produced by standard peptide synthesis techniques, such as solid-phase synthesis. A portion of the protein may contain an amino acid sequence such as a T7 tag or polyhistidine sequence to facilitate purification of expressed or synthesized protein. The protein may be expressed in a cell and purified. The protein may be expressed as a part of a larger protein (e.g., a fusion or chimera) by recombinant methods.
A novel ligand binding site of a TRAIL receptor or a novel ligand of a TRAIL receptor, or a subsequence, portion, homologue, variant or derivative thereof, can be made using recombinant DNA technology via cell expression or in vitro translation. Polypeptide sequences including modified forms can also be produced by chemical synthesis using methods known in the art, for example, an automated peptide synthesis apparatus (see, e.g., Applied Biosystems, Foster City, Calif.).
The invention provides isolated and/or purified novel ligand binding sites of a TRAIL receptor or novel ligands of a TRAIL receptor, or a subsequence, portion, homologue, variant or derivative thereof, including, comprising or consisting of amino acid sequence of a TRAIL-R1 receptor, a TRAIL-R2 receptor, a TRAIL-R3 receptor, a TRAIL-R4 receptor, a ligand of a TRAIL-R1 receptor, a ligand of a TRAIL-R2 receptor, a ligand of a TRAIL-R3 receptor or a ligand of a TRAIL-R4 receptor or a subsequence, portion, homologue, variant or derivative thereof.
In particular embodiments, the present invention provides an isolated and/or purified novel ligand binding site of a TRAIL-R2 receptor, or a subsequence, portion, homologue, variant or derivative thereof. In other embodiments, the present invention provides an isolated and/or purified novel ligand of a TRAIL-R2 receptor.
In certain embodiments, the present invention provides an isolated and/or purified novel ligand binding site of a TRAIL-R2 receptor, or a subsequence, portion, homologue, variant or derivative thereof, that includes, comprises, consists of or consists essentially of amino acid residues 58-184 of TRAIL-R2 receptor or a subsequence, portion, homologue, variant or derivative thereof. In certain embodiments, the present invention provides an isolated and/or purified novel ligand binding site of a TRAIL-R2 receptor, or a subsequence, portion, homologue, variant or derivative thereof, that includes, comprises, consists of or consists essentially of amino acid residues 185-212 of TRAIL-R2 receptor or a subsequence, portion, homologue, variant or derivative thereof. In particular embodiments, the present invention provides an isolated and/or purified novel ligand binding site of a TRAIL-R2 receptor, or a subsequence, portion, homologue, variant or derivative thereof, that includes, comprises, consists of or consists essentially of amino acid residues 58-212 of TRAIL-R2 receptor or a subsequence, portion, homologue, variant or derivative thereof. In other embodiments, the present invention provides an isolated and/or purified novel ligand binding site of a TRAIL-R2 receptor, or a subsequence, portion, homologue, variant or derivative thereof, that includes, comprises, consist of or consists essentially of structural coordinates set forth in
The term “isolated,” when used as a modifier of a composition (e.g., novel ligand binding sites of a TRAIL receptor or novel ligands of a TRAIL receptor, or a subsequence, portion, homologue, variant or derivative thereof, nucleic acids encoding same, etc.), means that the compositions are made by the hand of man or are separated, completely or at least in part, from their naturally occurring in vivo environment. Generally, isolated compositions are substantially free of one or more materials with which they normally associate with in nature, for example, one or more protein, nucleic acid, lipid, carbohydrate, cell membrane. The term “isolated” does not exclude alternative physical forms of the composition, such as fusions/chimeras, multimers/oligomers, modifications (e.g., phosphorylation, glycosylation, lipidation) or derivatized forms, or forms expressed in host cells produced by the hand of man.
An “isolated” composition (e.g., novel ligand binding sites of a TRAIL receptor or novel ligands of a TRAIL receptor, or a subsequence, portion, homologue, variant or derivative thereof) can also be “substantially pure” or “purified” when free of most or all of the materials with which it typically associates with in nature. Thus, an isolated novel ligand binding site of a TRAIL receptor or a novel ligand of a TRAIL receptor, or a subsequence, portion, homologue, variant or derivative thereof, that also is substantially pure or purified does not include polypeptides or polynucleotides present among millions of other sequences, such as peptides of an peptide library or nucleic acids in a genomic or cDNA library, for example.
A “substantially pure” or “purified” composition can be combined with one or more other molecules. Thus, “substantially pure” or “purified” does not exclude combinations of compositions, such as combinations of novel ligand binding sites of a TRAIL receptor or novel ligands of a TRAIL receptor, or a subsequence, portion, homologue, variant or derivative thereof, and other proteins, peptides, agents, drugs or therapies.
In accordance with the present invention, there are also provided methods of identifying a binding agent that will interact with the novel ligand binding sites of a TRAIL receptor described herein and binding agents that interact with the novel ligand binding site of a TRAIL receptor described herein.
As used herein, a “binding agent” includes agents that decrease, reduce, inhibit, suppress or disrupt binding of a TRAIL receptor to another ligand or binding agent. Agents also include agents that increase, enhance, stimulate, or promote binding of a TRAIL receptor to another ligand or binding agent. Furthermore, agents include antagonists and agonists of TRAIL receptor function or activity, i.e., agents that decrease, reduce, inhibit, suppress or disrupt a function or activity of a TRAIL receptor; or increase, enhance, stimulate, or promote a function or activity of a TRAIL receptor. In certain embodiments agents include antagonists and agonists of a TRAIL receptor ligand function or activity, i.e., agents that decrease, reduce, inhibit, suppress or disrupt a function or activity of a TRAIL receptor ligand; or increase, enhance, stimulate, or promote a function or activity of a TRAIL receptor ligand.
Non-limiting particular examples of agents include amino acid sequences, such as antibodies, proteins, peptides, and polypeptides, including fusion polypeptides and chimeric polypeptides. Non-limiting examples of agents also include nucleic acid sequences or polynucleotides/polynucleotides, including inhibitory nucleic acids. Further non-limiting examples of agents include ligand mimetics and small molecules. In certain embodiments, binding agents may bind to TRAIL receptor or a ligand of TRAIL receptor thereby modulating (altering or affecting) binding between the TRAIL receptor and a ligand of the TRAIL receptor, and in turn modulating TRAIL receptor activity.
In one aspect, the present invention provides methods of identifying a binding agent that will interact with a novel TRAIL receptor ligand binding site described herein. In certain embodiments, the present methods comprise providing a test agent; contacting the test agent with a protein or peptide comprising, consisting of or consisting essentially of amino acid residues 58-184 of the TRAIL-R2 receptor, or subsequence, portion, homologue, variant or derivative thereof; and detecting interaction of the test agent with the protein or peptide comprising, consisting of or consisting essentially of amino acid residues 58-184 of TRAIL-R2 receptor or subsequence, portion, homologue, variant or derivative thereof. In certain embodiments, the method comprises contacting the test agent with a protein or peptide comprising, consisting of or consisting essentially of amino acid residues 58-212 of the TRAIL-R2 receptor, or subsequence, portion, homologue, variant or derivative thereof; and detecting interaction of the test agent with the protein or peptide comprising, consisting of or consisting essentially of amino acid residues 58-212 of TRAIL-R2 receptor or subsequence, portion, homologue, variant or derivative thereof. In other embodiments, the method comprises contacting the test agent with a protein or peptide comprising, consisting of or consisting essentially of amino acid residues 185-212 of the TRAIL-R2 receptor, or subsequence, portion, homologue, variant or derivative thereof; and detecting interaction of the test agent with the protein or peptide comprising, consisting of or consisting essentially of amino acid residues 185-212 of TRAIL-R2 receptor or subsequence, portion, homologue, variant or derivative thereof. In specific embodiments, the methods comprise identifying a binding agent that interacts with one or more binding patches of the TRAIL-R2 receptor, the method comprising providing a test agent; contacting the test agent with a protein or peptide comprising, consisting of or consisting essentially of one or more the binding patches of the TRAIL-R2 receptor: detecting interaction of the test agent with the protein or peptide comprising, consisting of or consisting essentially of one or more of the binding patches of the TRAIL-R2 receptor, or a subsequence, portion, homologue, variant or derivative thereof. In certain embodiments of the methods described herein, the binding patches comprise, consist of or consist essentially of amino acid residues E78 and D109 of the TRAIL-R2 receptor; amino acid residue D148 of the TRAIL-R2 receptor; amino acid residues V167, V179 and W173 of the TRAIL-R2 receptor; amino acid residues Y103, N134 and R133 of the TRAIL-R2 receptor; amino acid residues L110, L114 and F112 of the TRAIL-R2 receptor; and/or amino acid residues E151 and E147 of the TRAIL-R2 receptor; or a subsequence, portion, homologue, variant or derivative thereof. In different embodiments of the present methods, the protein or peptide comprising, consisting of or consisting essentially of one or more of the binding patches of the TRAIL-R2 receptor, or a subsequence, portion, homologue, variant or derivative thereof, is a protein or peptide comprising ligand bindings sites or amino acid sequences of a TRAIL-R1 receptor, TRAIL-R3 receptor or TRAIL-R4 receptor that are homologous to ligand bindings sites or amino acid sequences of a TRAIL-R2 receptor, or a subsequence, portion, variant or derivative thereof.
The present invention provides cell-free (e.g., in solution, in solid phase) and cell-based (e.g., in vitro or in vivo) methods of identifying a binding agent that will interact with a novel ligand binding site of a TRAIL receptor and methods of identifying a binding agent that will modulate TRAIL receptor activity. The methods can be performed in solution, in solid phase, in silica, in silico, in vitro, in a cell, and in vivo.
As used herein, the term “modulate,” means an alteration or effect on the term modified. For example, the term modulate can be used in various contexts to refer to an alteration or effect of an activity, a function, or expression of a polypeptide, gene or signaling pathway, or a physiological condition or response of an organism. In certain embodiments of the present invention, modulating involves decreasing, reducing, inhibiting, suppressing or disrupting binding of a TRAIL receptor to another ligand or binding agent or function or activity of a TRAIL receptor or ligand thereof. In other embodiments of the present invention, modulating involves increasing, enhancing, stimulating, or promoting binding of a TRAIL receptor to another ligand or binding agent or function or activity of a TRAIL receptor or ligand thereof. Thus, where the term “modulate” is used to modify the term “binding of a TRAIL receptor to a ligand” this means that binding of the TRAIL receptor to a ligand is altered or affected (e.g., decreased, reduced, inhibited, suppressed, limited, controlled, prevented, stimulated, increased or enhanced etc.).
Also provided by the present invention are methods comprising the binding agents or novel ligands of a TRAIL receptor, or a subsequence, portion, homologue, variant or derivative thereof, described herein, or an agonist or antagonist thereof. In one aspect, there is presently provided a method for modulating the activity of a TRAIL receptor, the method comprising contacting the TRAIL receptor with a binding agent or novel ligand of a TRAIL receptor, or a subsequence, portion, homologue, variant or derivative thereof, described herein, or an agonist or antagonist thereof. Methods and uses of the present invention can be performed in vivo, such as in a subject, in vitro, ex vivo, in a cell, in solution, in solid phase, in silico or in silica. In different embodiments of the present methods, the TRAIL receptor is expressed on a cell present in vivo or in vitro.
In different embodiments of the present methods, the activity of a TRAIL receptor may be modulated to decrease, reduce, inhibit, suppress, disrupt, elicit, stimulate, induce, promote, increase or enhance TRAIL receptor activity. In particular embodiments, the TRAIL receptor activity modulated is an immune response, an anti-inflammatory response, cell proliferation or an apoptotic response mediated by the TRAIL receptor or a ligand thereof.
The present invention also provides methods of treatment comprising administration to a subject of a binding agent or novel ligands of a TRAIL receptor, or a subsequence, portion, homologue, variant or derivative thereof, described herein, or an agonist or antagonist thereof.
In certain embodiments, the present methods comprise for treating an undesirable or aberrant immune response, immune disorder, inflammatory response, inflammation or an autoimmune response, disorder or disease in a subject.
In various aspects of the presently provided methods, a subject has or has had an adverse symptom of an undesirable or aberrant immune response, immune disorder, inflammatory response, inflammation or an autoimmune response, disorder or disease.
In additional various aspects of methods and uses of the invention, a subject is in need of treatment for an undesirable or aberrant immune response, immune disorder, inflammatory response, inflammation or an autoimmune response, disorder or disease.
In further various aspects of methods and uses of the invention, a subject is at risk of an undesirable or aberrant immune response, immune disorder, inflammatory response, inflammation or an autoimmune response, disorder or disease.
As used herein, an “undesirable immune response” or “aberrant immune response” refers to any immune response, activity or function that is greater or less than desired or physiologically normal, acute or chronic. An undesirable immune response, function or activity can be a normal response, function or activity. However, such responses are generally characterized as an undesirable or aberrant increased or inappropriate response, activity or function of the immune system. Thus, normal immune responses so long as they are undesirable, even if not considered aberrant, are included within the meaning of these terms. An undesirable immune response, function or activity can also be an abnormal response, function or activity. An abnormal (aberrant) immune response, function or activity deviates from normal.
One non-limiting example of an undesirable or aberrant immune response is where the immune response is hyper-responsive, such as in the case of an autoimmune disorder or disease. Another example of an undesirable or aberrant immune response is where an immune response leads to acute or chronic inflammatory response or inflammation in any tissue or organ.
Undesirable or aberrant immune responses, inflammatory responses, or inflammation are characterized by many different physiological adverse symptoms or complications, which can be humoral, cell-mediated or a combination thereof. Responses, disorders and diseases that can be treated in accordance with the invention include, but are not limited to, those that either directly or indirectly lead to or cause cell or tissue/organ damage in a subject. At the whole body, regional or local level, an immune response, inflammatory response, or inflammation can be characterized by swelling, pain, headache, fever, nausea, skeletal joint stiffness or lack of mobility, rash, redness or other discoloration. At the cellular level, an immune response, inflammatory response, or inflammation can be characterized by one or more of T cell activation and/or differentiation, cell infiltration of the region, production of antibodies, production of cytokines, lymphokines, chemokines, interferons and interleukins, cell growth and maturation factors (e.g., proliferation and differentiation factors), cell proliferation, accumulation or migration and cell, tissue or organ damage. Thus, methods and uses of the invention include treatment of and an ameliorative effect upon any such physiological symptoms or cellular or biological responses characteristic of immune responses, inflammatory response, or inflammation.
Autoimmune responses, disorders and diseases are generally characterized as an undesirable or aberrant response, activity or function of the immune system characterized by increased or undesirable humoral or cell-mediated immune responsiveness or memory, or decreased or insufficient tolerance to self-antigens. Autoimmune responses, disorders and diseases that may be treated in accordance with the invention include but are not limited to responses, disorders and diseases that cause cell or tissue/organ damage in the subject. The terms “immune disorder” and “immune disease” mean, an immune function or activity which is characterized by different physiological symptoms or abnormalities, depending upon the disorder or disease.
In particular embodiments, a method or use decreases, reduces, inhibits, suppresses, limits or controls an undesirable or aberrant immune response, disorder or disease, inflammatory response, disorder or disease, or inflammation, in a subject. In additional particular embodiments, a method or use decreases, reduces, inhibits, suppresses, limits or controls an autoimmune response, disorder or disease in a subject.
In further particular embodiments, a method or use decreases, reduces, inhibits, suppresses, limits or controls an adverse symptom of the undesirable or aberrant immune response, disorder or disease, inflammatory response, disorder or disease, inflammation, or an autoimmune response, disorder or disease.
In additional particular embodiments, methods and uses according to the invention can result in a reduction in occurrence, frequency, severity, progression, or duration of a symptom of the condition (e.g., undesirable or aberrant immune response, disorder or disease, inflammatory response, disorder or disease, inflammation, or an autoimmune response, disorder or disease). For example, methods of the invention can protect against or decrease, reduce, inhibit, suppress, limit or control progression, severity, frequency, duration or probability of an adverse symptom of the undesirable or aberrant undesirable or aberrant immune response, disorder or disease, inflammatory response, disorder or disease, inflammation, or an autoimmune response, disorder or disease.
Examples of adverse symptoms of an undesirable or aberrant immune response, disorder or disease, inflammatory response, disorder or disease, inflammation, or an autoimmune response, disorder or disease include swelling, pain, rash, discoloration, headache, fever, nausea, diarrhea, bloat, lethargy, skeletal joint stiffness, reduced muscle or limb mobility or of the subject, paralysis, a sensory impairment, such as vision or tissue or cell damage. Examples of adverse symptoms occur in particular tissues, or organs, or regions or areas of the body, such as in skin, epidermal or mucosal tissue, gut, gastrointestinal, bowel, genito-urinary tract, pancreas, thymus, lung, liver, kidney, muscle, central or peripheral nerves, spleen, skin, a skeletal joint (e.g., knee, ankle, hip, shoulder, wrist, finger, toe, or elbow), blood or lymphatic vessel, or a cardio-pulmonary tissue or organ. Additional examples of adverse symptoms of an autoimmune response, disorder or disease include cell production, survival, proliferation, activation or differentiation, and/or production of auto-antibodies, or pro-inflammatory cytokines or chemokines (e.g., TNF-alpha, IL-6, etc.).
Specific non-limiting examples of aberrant or undesirable immune responses, disorders and diseases, inflammatory responses, disorders and diseases, inflammation, autoimmune responses, disorders and diseases, treatable in accordance with the invention include: comprises rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis, multiple sclerosis (MS), encephalomyelitis, myasthenia gravis, systemic lupus erythematosus (SLE), asthma, allergic asthma, autoimmune thyroiditis, atopic dermatitis, eczematous dermatitis, psoriasis, Sjögren's Syndrome, Crohn's disease, aphthous ulcer, iritis, conjunctivitis, keratoconjunctivitis, ulcerative colitis (UC), inflammatory bowel disease (IBD), cutaneous lupus erythematosus, scleroderma, vaginitis, proctitis, erythema nodosum leprosum, autoimmune uveitis, allergic encephalomyelitis, acute necrotizing hemorrhagic encephalopathy, idiopathic bilateral progressive sensorineural hearing loss, aplastic anemia, pure red cell anemia, idiopathic thrombocytopenia, polychondritis, Wegener's granulomatosis, chronic active hepatitis, Stevens-Johnson syndrome, idiopathic sprue, lichen planus, Graves' disease, sarcoidosis, primary biliary cirrhosis, uveitis posterior, interstitial lung fibrosis, Hashimoto's thyroiditis, autoimmune polyglandular syndrome, insulin-dependent diabetes mellitus (IDDM, type I diabetes), insulin-resistant diabetes mellitus (type II diabetes), immune-mediated infertility, autoimmune Addison's disease, pemphigus vulgaris, pemphigus foliaceus, dermatitis herpetiformis, autoimmune alopecia, vitiligo, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, pernicious anemia, Guillain-Barre syndrome, stiff-man syndrome, acute rheumatic fever, sympathetic ophthalmia, Goodpasture's syndrome, systemic necrotizing vasculitis, antiphospholipid syndrome or an allergy, Behcet's disease, severe combined immunodeficiency (SCID), recombinase activating gene (RAG 1/2) deficiency, adenosine deaminase (ADA) deficiency, interleukin receptor common γ chain (yc) deficiency, Janus-associated kinase 3 (JAK3) deficiency and reticular dysgenesis; primary T cell immunodeficiency such as DiGeorge syndrome, Nude syndrome, T cell receptor deficiency, MHC class II deficiency, TAP-2 deficiency (MHC class I deficiency), ZAP70 tyrosine kinase deficiency and purine nucleotide phosphorylase (PNP) deficiency, antibody deficiencies, X-linked agammaglobulinemia (Bruton's tyrosine kinase deficiency), autosomal recessive agammaglobulinemia, Mu heavy chain deficiency, surrogate light chain (γ5/14.1) deficiency, Hyper-IgM syndrome: X-linked (CD40 ligand deficiency) or non-X-linked, Ig heavy chain gene deletion, IgA deficiency, deficiency of IgG subclasses (with or without IgA deficiency), common variable immunodeficiency (CVID), antibody deficiency with normal immunoglobulins; transient hypogammaglobulinemia of infancy, interferon γ receptor (IFNGR1, IFNGR2) deficiency, interleukin 12 or interleukin 12 receptor deficiency, immunodeficiency with thymoma, Wiskott-Aldrich syndrome (WAS protein deficiency), ataxia telangiectasia (ATM deficiency), X-linked lymphoproliferative syndrome (SH2D1A/SAP deficiency), or hyper IgE syndrome.
In certain embodiments, the methods of treatment provided herein comprise treating a microbial infection in a subject, including but not limited to a bacterial infection or a viral infection, or an adverse symptom thereof. In other embodiments, there are provided methods of treating a tumor or cancer in a subject, or an adverse symptom thereof. In still further embodiments, there are provided methods of treating a vascular disease in a subject, including but not limited to pulmonary arterial hypertension, or an adverse symptom thereof.
In different embodiments, the methods of treatment presently provided comprise decreasing, reducing, inhibiting, suppressing, disrupting, eliciting, stimulating, inducing, promoting, increasing or enhancing TRAIL receptor activity. In particular embodiments, the TRAIL receptor activity modulated is an immune response, an anti-inflammatory response, cell proliferation or an apoptotic response mediated by the TRAIL receptor or a ligand thereof.
“Treating” or “treatment of” a condition, disease or disorder or symptoms associated with a condition, disease or disorder refers to an approach for obtaining beneficial or desired results, including clinical results. Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of condition, disorder or disease, stabilization of the state of condition, disorder or disease, prevention of development of condition, disorder or disease, prevention of spread of condition, disorder or disease, delay or slowing of condition, disorder or disease progression, delay or slowing of condition, disorder or disease onset, amelioration or palliation of the condition, disorder or disease state, and remission, whether partial or total. “Treating” can also mean prolonging survival of a subject beyond that expected in the absence of treatment. “Treating” can also mean inhibiting the progression of the condition, disorder or disease, slowing the progression of the condition, disorder or disease temporarily, although in some instances, it involves halting the progression of the condition, disorder or disease permanently.
Binding agents and novel TRAIL receptor ligands or a subsequence, portion, homologue, variant or derivative thereof of the present invention, can be administered in a sufficient or effective amount to a subject in need thereof. An “effective amount” or “sufficient amount” refers to an amount that provides, or is predicted to provide, in single or multiple doses, alone or in combination, with one or more other compositions (therapeutic agents such as a drug), treatments, protocols, or therapeutic regimens agents, a detectable response of any duration of time (long or short term), an expected or desired outcome in or a benefit to a subject of any measurable or detectable degree or for any duration of time (e.g., for minutes, hours, days, months, years, or cured).
Invention agents and ligands, or a subsequence, portion, homologue, variant or derivative thereof, and agents and ligands, or subsequence, portion, homologue, variant or derivative thereof, of the methods described herein can be in various physical forms therein, such as a liquid or solid form. Invention agents, and agents of the methods described herein, can include any amount or dose of the agent, and the agent. In particular embodiments, an agent is in a concentration range of about 10 μg/ml to 100 mg/ml, or in a range of about 100 μg/ml to 1,000 mg/ml, or at a concentration of about 1 mg/ml. In further particular embodiments, an agent is in an amount of 10-1,000 milligrams, or an amount of 10-100 milligrams.
The doses of an “effective amount” or “sufficient amount” for treatment (e.g., to ameliorate or to provide a therapeutic benefit or improvement) typically are effective to ameliorate a response, disorder or disease, or one, multiple or all adverse symptoms, consequences or complications of the response, disorder or disease, one or more adverse symptoms, disorders, illnesses, pathologies, diseases, or complications, for example, caused by or associated with an aberrant immune response to a measurable extent, although decreasing, reducing, inhibiting, suppressing, limiting or controlling progression or worsening of the aberrant immune response is a satisfactory outcome.
An effective amount or a sufficient amount can but need not be provided in a single dose or administration, may require multiple doses or administrations, and, can but need not be, administered alone or in combination with another composition (e.g., agent), treatment, protocol or therapeutic regimen. For example, the amount may be proportionally increased as indicated by the need of the subject, type, status and severity of the response, disorder, or disease treated or side effects (if any) of treatment. In addition, an effective amount or a sufficient amount need not be effective or sufficient if given in single or multiple doses without a second composition (e.g., another drug or agent), treatment, protocol or therapeutic regimen, since additional doses, amounts or duration above and beyond such doses, or additional compositions (e.g., drugs or agents), treatments, protocols or therapeutic regimens may be included in order to be considered effective or sufficient in a given subject. Amounts considered effective also include amounts that result in a reduction of the use or frequency or amount of another treatment, therapeutic regimen or protocol.
In certain embodiments of the methods of the present invention, binding agents or novel TRAIL receptor ligands, or subsequences, portions, homologues, variants or derivatives thereof, described herein are administered in combination with another TRAIL receptor binding agent. In particular embodiments of the present methods, binding agents or novel TRAIL receptor ligands, or subsequences, portions, homologues, variants or derivatives thereof, described herein are administered in combination with an agonist of the TRAIL receptor ligand. In certain embodiments, the other TRAIL receptor binding agent binds a different binding site on the TRAIL receptor ligand then the binding agents or novel TRAIL receptor ligands, or subsequences, portions, homologues, variants or derivatives thereof, presently described. In particular embodiments of the present methods, binding agents or novel TRAIL receptor ligands, or subsequences, portions, homologues, variants or derivatives thereof, described herein are administered in combination with an agonist of the TRAIL receptor ligand. In one embodiment, binding agents or novel TRAIL receptor ligands, or subsequences, portions, homologues, variants or derivatives thereof, described herein are administered in combination with an TRAIL receptor agonist that binds the same binding site of the TRAIL receptor as TRAIL. In still a further embodiment, the present methods comprise a bispecific molecule, including but not limited to a bispecific antibody, that binds both the novel ligand binding site of a TRAIL receptor described herein and an alternative ligand binding site of the same TRAIL receptor. In particular embodiments, the bispecific molecule inhibits binding of a ligand to the novel ligand binding site of a TRAIL receptor described herein and agonizes TRAIL receptor activity by binding an alternative ligand binding site of the TRAIL receptor.
An effective amount or a sufficient amount need not be effective in each and every subject treated, prophylactically or therapeutically, nor a majority of treated subjects in a given group or population. An effective amount or a sufficient amount means effectiveness or sufficiency in a particular subject, not a group or the general population. As is typical for such methods, some subjects will exhibit a greater response, or less or no response to a given treatment method or use. Thus, appropriate amounts will depend upon the condition treated, the therapeutic effect desired, as well as the individual subject (e.g., the bioavailability within the subject, gender, age, etc.).
As used herein the term “subject” refers to animals, typically mammalian animals, such as humans, non human primates (e.g., apes, gibbons, chimpanzees, orangutans, macaques), domestic animals (e.g., dogs and cats), farm animals (e.g., horses, cows, goats, sheep, pigs) and experimental animals (e.g., mouse, rat, rabbit, guinea pig). Subjects include animal disease models, for example, animal models of an aberrant immune response, disorder or disease for in vivo analysis of an agent of the invention.
Binding agents and novel TRAIL receptor ligands, or subsequences, portions, homologues, variants or derivatives thereof, described herein can be administered to a subject and methods may be practiced prior to, substantially contemporaneously with, or within about 1-60 minutes, hours (e.g., within 1, 2, 3, 4, 5, 6, 8, 12, 24 hours), or days of a symptom or onset of an aberrant immune response, disorder or disease.
A binding agent or novel TRAIL receptor ligand, or subsequences, portions, homologues, variants or derivatives thereof, of the present invention can be administered and methods presently provided can be practiced via systemic, regional or local delivery or administration, by any route. For example, a binding agent, novel TRAIL receptor ligand or composition thereof may be administered systemically, regionally or locally, via injection, infusion, orally (e.g., ingestion or inhalation), topically, intravenously, intraarterially, intramuscularly, intraperitoneally, intradermally, subcutaneously, intracavity, intracranially, transdermally (topical), parenterally, e.g. transmucosally or intrarectally (enema) catheter, optically.
In certain aspects of the present invention there is presently provided pharmaceutical compositions comprising a binding agent or novel TRAIL receptor ligand or subsequences, portions, homologues, variants or derivatives thereof, described herein, or an agonist or antagonist thereof, and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers such as saline will be known to a person of skill in the art. Binding agents, novel TRAIL receptor ligands, or subsequences, portions, homologues, variants or derivatives thereof, and methods of the present invention may comprise pharmaceutical formulations that can be administered via a (micro)encapsulated delivery system or packaged into an implant for administration.
As used herein, the term “pharmaceutically acceptable” when referring to carriers, diluents or excipients includes solvents (aqueous or non-aqueous), detergents, solutions, emulsions, dispersion media, coatings, isotonic and absorption promoting or delaying agents, compatible with pharmaceutical administration and with the other components of the formulation, and can be contained in a tablet (coated or uncoated), capsule (hard or soft), microbead, emulsion, powder, granule, crystal, suspension, syrup or elixir.
The present invention also provides the a novel composition comprising TRAIL receptor bound to a ligand in crystalline form and a novel crystallized complex of a TRAIL receptor and a ligand thereof. In certain embodiments, the TRAIL receptor is TRAIl-R2. In certain embodiments, the novel composition or crystallized complex comprises the relative structural coordinates set forth in
In certain embodiments, the novel composition comprising TRAIL-R2 receptor bound to a ligand in crystalline form or novel crystallized complex of a TRAIL-R2 receptor and a ligand thereof has unit cell parameters of a=67.74 Å, b=97.01 Å and c=140.94 Å or a=67.71 Å, b=97.67 Å, c=141.31 Å.
In another aspect of the present invention, there is provided a crystallized complex of a novel ligand binding site of a TRAIL receptor described herein. In particular embodiments, the crystallized complex of a novel ligand binding site of a TRAIL receptor comprises a novel ligand binding site of a TRAIL-R2 receptor. In certain embodiments, the crystallized complex of a novel ligand binding site of a TRAIL receptor comprises relative structural coordinates set forth in
Also provided are methods of use of the novel composition comprising a TRAIL receptor bound to a ligand in crystalline form or the novel crystallized complex of a TRAIL receptor and a ligand thereof described herein for designing a compound, protein or peptide that interacts with the TRAIL receptor.
As will be understood by a person of skill in the art, in particular embodiments, the method of use of a novel composition comprising a TRAIL receptor bound to a ligand in crystalline form or a novel crystallized complex of a TRAIL receptor and a ligand thereof described herein for designing a compound, protein or peptide that interacts with the TRAIL receptor is computer implemented. Thus in particular embodiments, a computer system is used to represent a novel composition comprising a TRAIL receptor bound to a ligand in crystalline form or a novel crystallized complex of a TRAIL receptor and a ligand thereof described herein to design a compound, protein or peptide that interacts with the TRAIL receptor, the computer system including data storage means including data corresponding to the coordinates of the novel composition comprising a TRAIL receptor bound to a ligand in crystalline form or a novel crystallized complex of a TRAIL receptor and a ligand thereof described herein. In particular embodiments, the coordinates comprise the coordinates set forth in
In certain embodiments, the computer system is arranged to provide a representation of a three-dimensional structure of the novel composition comprising a TRAIL receptor bound to a ligand in crystalline form or the novel crystallized complex of a TRAIL receptor and a ligand thereof described herein. The computer system may include a display for displaying a representation of the three-dimensional structure of the novel composition comprising a TRAIL receptor bound to a ligand in crystalline form or a novel crystallized complex of a TRAIL receptor and a ligand thereof described herein.
All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually incorporated herein by reference in their entirety. In case of conflict, the specification, including definitions, will control. The citation of any publication is not to be construed as an admission that the invention is not entitled to antedate such publication by virtue of prior invention.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, suitable methods and materials are described herein.
As used herein, the singular forms “a”, “and,” and “the” include plural referents unless the context clearly indicates otherwise. Thus, for example, reference to “an agent” such as an “antibody” or an “inhibitory nucleic acid” or a “small molecule” includes a plurality of such agents, and reference to “an activity or function” can include reference to one or more activities or functions, and so forth.
As used in this specification and the appended claims, the terms “comprise,” “comprising,” “comprises” and grammatical variations of these terms are intended in the non-limiting inclusive sense, that is, to include the particular recited elements or components without excluding any other element or component.
Concentrations used herein, when given in terms of percentages, include weight/weight (w/w), weight/volume (w/v) and volume/volume (v/v) percentages.
As used herein, numerical values are often presented in a range format throughout this document. The use of a range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the use of a range expressly includes all possible subranges and all individual numerical values within that range. Furthermore, all numerical values or numerical ranges include integers within such ranges and fractions of the values or the integers within ranges unless the context clearly indicates otherwise. This construction applies regardless of the breadth of the range and in all contexts throughout this patent document. Thus, for example, reference to a range of 90-100% includes 91-99%, 92-98%, 93-95%, 91-98%, 91-97%, 91-96%, 91-95%, 91-94%, 91-93%, and so forth. Reference to a range of 90-100%, includes 91%, 92%, 93%, 94%, 95%, 95%, 97%, etc., as well as 91.1%, 91.2%, 91.3%, 91.4%, 91.5%, etc., 92.1%, 92.2%, 92.3%, 92.4%, 92.5%, etc., and so forth. In addition, reference to a range of 1-5,000 fold includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, etc., . . . . 5,000 fold, etc., as well as 1.1, 1.2, 1.3, 1.4, 1.5, fold, etc., 2.1, 2.2, 2.3, 2.4, 2.5, fold, etc., and any numerical range within such a ranges, such as 1-2, 3-5, 5-10, 10-50, 50-100, 100-500, 100-1000, 500-1000, 1000-2000, 1000-5000, etc.
As also used herein a series of range formats are used throughout this document. The use of a series of ranges includes combinations of the upper and lower ranges to provide a range. This construction applies regardless of the breadth of the range and in all contexts throughout this patent document. Thus, for example, reference to a series of ranges such as 5 to 10, 10 to 20, 20 to 30, 30, to 50, 50 to 100, 100 to 150, 150 to 200, 200 to 300, or 300 to 400, 400-500, 500-600, or 600-705, includes all combinations of the different ranges such as 5-20, 5-30, 5-40, 5-50, 5-75, 5-100, 5-150, 5-171, and 10-30, 10-40, 10-50, 10-75, 10-100, 10-150, 10-171, and 20-40, 20-50, 20-75, 20-100, 20-150, 20-200, 50 to 200, 50 to 300, 50, to 400, 50 to 500, 100 to 300, 100 to 400, 100 to 500, 100 to 600, 200-400, 200-500, 200 to 600, 200 to 700, and so forth.
The invention is generally disclosed herein using affirmative language to describe the numerous embodiments. The invention also specifically includes embodiments in which particular subject matter is excluded, in full or in part, such as substances or materials, method steps and conditions, protocols, procedures, assays or analysis. Thus, even though the invention is generally not expressed herein in terms of what the invention does not include aspects that are not expressly included in the invention are nevertheless disclosed herein.
A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, the following examples, which include data demonstrating a physiological interaction of TRAIL-R2 receptor and UL141 are intended to illustrate but not limit the scope of invention described in the claims.
Design of Expression Constructs—U1141, TRAIL-R2
The mature ectodomains of UL141 (amino acids (aa) 30-279 and 30-217, HCMV FIX strain) and TRAIL-R2 (DR5; aa 58-184) were PCR amplified and cloned downstream of the gp67 signal sequence into the baculovirus transfer vector pAcGP67A (BD biosciences) upstream of the Fc domain of human IgG1 (pAc-gp67A-MCS-Thr-Fc; for use in Biacore). A thrombin protease cleavage site (LVPRGS) was also introduced between the individual ectodomain and the Fc fusion protein. In parallel, both UL141 ectodomain constructs were also cloned in pAcGP67A containing only a C-terminal poly-histidine tag. The UL141 constructs were amplified by polymerase chain reaction (PCR) using human cytomegalovirus (HCMV) cDNA as a template. For amplification of TRAIL-R2, human full-length cDNA was used as a PCR template. A nested PCR protocol with two pairs of primers was used to generate the constructs (Table 4). One pair of primers (hcmvUL141/30for/BamHI and hcmvUL141/217rev/His/EcoRI) generated a DNA product coding for residues 30-217 of UL141 followed by C-terminal polyhistidine-tag, where forward primer introduced a BamHI restriction site and the reverse primer an EcoRI restriction site with preceding stop codon. Similarly, the second pair of primers (hcmvUL141/30for/BamHI and hcmvUL141/279rev/His/EcoRI) generated a DNA fragment coding for residues 30-279 of UL141. The Fc-fusion expression constructs were generated by amplifying corresponding DNA genes and further ligated into the C-terminal Fc-fusion protein containing baculovirus transfer vector (pAc-gp67A-MCS-Thr-Fc). The following pairs of primers were used in PCR: TRAIL-R2 58-184 gene (huTRAIL-R2-Fc/58for/EcoRI and huTRAIL-R2-Fc/184rev/PstI), UL141 37-247 gene (hcmvUL141-Fc/37for/EcoRI and hcmvUL141-Fc/247rev/PstI) and UL141 37-273 gene (hcmvUL141-Fc/37for/EcoRI and hcmvUL141-Fc/273rev/PstI). The identity and correct sequence of all PCR-amplified constructs was confirmed by sequencing.
Preparation of Recombinant Baculoviruses
The baculovirus transfer vector pAcGP67A containing the UL141 or TRAIL-R2 expression construct was amplified in bacteria (E. coli DH5α) and maintained under sterile conditions. To increase transfection efficiency, transfection was performed in serum-free media (HyClone SFXlnsect Cell Culture Media, Thermo Scientific) without any antibiotics using Cellfectin reagent (Invitrogen) according to manufacturer's instructions. The transfection complex was formed as follows: 2 μg of recombinant DNA (UL141 or TRAIL-R2 in transfer vector)+0.1 μg of BaculoGold DNA (Invitrogen)+10 μl of Cellfectin Reagent were filled up to 1 ml with media. As a negative control, 20 μl of Cellfectin+1 ml media was mixed. The transfection mixture was vigorously vortexed for 30 sec and incubated at RT for 15 min in the dark. 2×106 healthy-dividing Spodoptera frugiperda (SF)9 cells were seeded in T-25 (25 cm2) flasks. Culture media was removed and transfection mixture was added drop-wise. Transfection plates were then incubated at RT for 4 hours while rocking back-and-forth every 30 min in dark. After 4 hours, the transfection mixture was replaced with 5 ml fresh media containing antibiotics (mixture of 50 U/ml of penicillin and 50 μg/ml of streptomycin) and plates were incubated at 28° C. for 7 days. For the initial screening for positive recombinant UL141 or TRAIL-R2 virus the dilution virus pool method was applied. Positive recombinant virus was selected and then amplified as follows. Cell supernatant containing recombinant virus was collected (1000×g for 10 min) and used for first round of virus amplification. 300 μl of virus with a multiplicity of infection below 1 (MOI<l) was used to infect 2×106 cells in T-25 flask and the flask was then incubated at 28° C. After 5 days, the second virus amplification was performed in T-175 flask to infect 14×106 cells with volume of 1.5 ml of collected virus from the first amplification (MOI<l) in 50 ml of media and incubated for additional 5 days at 28° C. Virus titer was determined by end-point dilution assay (EPDA). Prior to expression, the high titer virus stock was prepared in several T-175 flasks by infection at MOI=1 of 14×106 cells in total 50 ml volume of media and incubated for 6 days at 28° C. Each flask was then directly used for infection of 2500×106 cells in total 1 L volume of media (MOI between 3 to 5) and incubated for 72 to 84 h at 28° C. as a suspension culture (at 138 rpm).
Expression of Seleno-Methionine Labeled UL141-TRAIL-R2-Fc Complex
Recombinant virus stock containing both UL141 and TRAIL-R2-Fc virus particles was prepared similar to the individual virus stocks (see above). To achieve equal protein synthesis via baculovirus mediated co-expression in Sf9, we prepared the transfection mixture under the following condition: 2 μg of UL141 recombinant DNA+2 μg of TRAIL-R2 Fc-fusion recombinant DNA (both in separate transfer vectors)+0.5 μg of BaculoGold DNA (Invitrogen)+20 μl of Cellfectin Reagent, filled up to 1 ml with media and as a control, 20 μl of Cellfectin+1 ml media was mixed. The first round of virus amplification was done by infecting the Sf9 cells, which were previously adapted for vital growth in ESF-921 protein-free media (Expression systems, Inc.), with heterologous virus from a 7-day transfection at 28° C. Similarly, the second virus amplification and the high titer virus stocks were prepared in several T-175 flasks by infection at MOI=1 of 14×106 cells in total 50 ml volume of ESF-921 media and incubated for 6 days at 28° C. Each flask was then directly used for infection of 3500×106 cells in total 1 L volume of ESF-921 methionine-rich media (MOI between 3 to 5) and incubated for 16 hours at 28° C. as a suspension culture (at 138 rpm). To achieve depletion of methionine from intracellular pools, cells were collected at 300 g for 15 min at RT and resuspended in ESF-921 methionine-free media with antibiotics (50 μg/mL gentamycin). Subsequently, seleno-methionine (50 mg/L) was added, to the suspension culture at 28° C. The critical point of seleno-methionine addition is within the first 16-20 hours following viral infection, as the protein expressing begins at that time. Expression of seleno-methionine labeled UL141-TRAIL-R2 Fc-fusion protein complex was continued for 48-96 hours post-infection (total time of expression 3.5 days at 28° C.). The culture media containing the seleno-methionine labeled protein complex was separated from cells by centrifugation (1000 g for 10 min) and debris was removed by additional centrifugation at 5500 g for 10 min at 4° C.
Expression of UL141 Fc and CD155 Fc- and TRAIL-R1 Fc-Fusion Proteins
Fc-fusion proteins were produced in baculovirus mediated insect cell expression system as well as in mammalian 293T cells. For 293T cells, DNA was prepared using the Endofree Plasmid Maxi kit (Qiagen, Valencia, Calif., USA) and maintained under the sterile condition. The confluent 293T cells were passaged in T-175 flasks in D10 media and incubated at 37° C. with 5% CO2. As a detaching component, 0.05% trypsin-EDTA solution was used to further maintain the cells. 293T cells were transfected by standard calcium phosphate transfection method and subsequently maintained for 72 h. The transfection mixture containing 100 μl of 2.5 M CaCl2, 22 μg DNA filled up to 1 ml with sterile water (calculation for one T-175 plate) was bubbled into 1 ml of 2×HeBS buffer (containing phosphate) and drop-wise transferred to seeded 293T cell in T-175 flask containing 25 ml D10 medium. After one day of transfection the media was changed to 30 ml CellGro media containing antibiotics and L-glutamine. After 48 hours of expression, the media was changed to fresh and supernatant was collected for harvesting, while rest of the cells in fresh media continues for next 24 hours expression. UL141 Fc protein was purified from cell culture supernatant using a HiTrap Protein A HP column (Amersham Biosciences, Piscataway, N.J., USA), while CD155-Fc and TRAIL-R1 Fc were used directly from culture supernatant for SPR studies (see below).
HEK293T Cell Culture
HEK293T cells were grown in Dulbeccos's modified medium (DMEM) supplemented with 10% (v/v) fetal calf serum (FCS), 2 mM L-glutamine and 100 units/ml of penicillin, 100 μg/ml of streptomycin (all together are components of D10 medium). Transfected 293T cells were further maintained in CellGro serum-free, protein-free media (CellGro, Mediatech).
Western Blots
Fc-fusion and His-tagged proteins were run on SDS gradient polyacrylamide gels and transferred to nitrocellulose membranes. Blots were probed with anti human IgG-HRP conjugate for UL141-Fc, CD155-Fc and TRAIL-R2-Fc (BioRad), or with mouse anti-penta-His conjugate and anti-mouse IgG HRP conjugate antibodies (Sigma).
Purification of UL141-TRAIL-R2 Complex (SeMet-Labeled and Native)
The extracellular domains of TRAIL-R2 and UL141 were cloned into transfer vector pAcGP67A engineered with C-terminal Fc-fusion tag in case of TRAIL-R2 and His-tag for UL141 construct. The proteins were co-expressed via the baculovirus expression system as a non-covalent protein complex, while a cleavage site for thrombin protease was introduced between TRAIL-R2 and the Fc portion of human IgG1. After three days of expression in insect cell media at 28° C., Sf9 cells and debris was removed from the protein containing culture supernatant by centrifugation. The supernatant was concentrated to 500 ml while the buffer was exchanged against 1×PBS by tangential flow-through filtration using 10 kDa molecular weight cut-off membranes (Millipore filtration device, Pelicon-2). Briefly, the UL141-TRAIL-R2-Fc complex was purified by affinity chromatography using Protein A (HiTrap Protein A), followed by Ni2+-affinity chromatography using HisTrap (both GE Healthcare), to purify the protein complex, rather than the individual components (
Crystallization of UL141-TRAIL-R2 Protein Complex (Native and SeMet-Labeled)
The UL141-TRAIL-R2 containing fractions for both native and selenomethionine labeled protein were pooled and concentrated to final concentrations of 7.3 mg/ml (native) and 8.3 mg/ml (labeled) in 50 mM HEPES, 150 mM NaCl, pH7.5. Initial crystallization trials were carried out by robotic crystallization (Phoenix, Art Robbins Instruments) using the sitting drop vapor diffusion method at room temperature as well as 4° C. Over 700 conditions were screened using several different commercial crystallization screens (Wizard I, II, III; PEG-ion 1, 2; JSCG I-IV and Core; Hampton Research Additive Screen) to find several initial crystallization hits for UL141-TRAIL-R2 native and one condition for labeled complex. Three-dimensional native and derivative crystals of the UL141-TRAIL-R2 protein complex were grown at 22° C. in the presence of high pH buffer (CHES 9.5 and bicine 9.0, respectively) and 20 (w/v) polyethylene glycol (8000 and 6000, respectively). The derivative condition also includes 0.2 M calcium chloride and 5-10% glycerol as an additive. These crystals were further optimized by macro- and micro-seeding techniques, as well as by crystallization under oil to improve diffraction quality. Crystallization under oil and crystallization with glycerol were the most successful optimization. A 5-8 μl drop containing a 1:1 mixture of Silicon and Paraffin Oil (Hampton Research), also known as Al's Oil, was placed as sitting drop. Next, the protein and precipitant (see above) was mixed 1:1 and pipetted under the oil. Reservoir was filled up with 1 ml of precipitant solution. Crystals were grown slowly over several days to maximal dimensions of approximately 1000×30×40 μm.
Data Collection and Processing—UL141-TRAIL-R2 Native and Derivative Data
Crystals were cryo-protected in well solution containing 25% glycerol and then flash-cooled in liquid nitrogen for data collection at 100 K. X-ray diffraction data were collected from the six best diffracting crystals at the Stanford Synchrotron Radiation Lightsource (SSRL) beamline 7-1 after testing crystals by excitation scan at Se-K edge for Se incorporation. The wavelength used for data collection was at the peak of Se f″ (0.9795 Å, 12667 keV). The inverse-beam mode of data collection was used with 7 sec exposure time (the crystal was rotated 180° every 10 frames to measure Friedel mates). To better resolve the reflections corresponding to the long axis, the crystals were aligned in the loop with the long axis roughly parallel to the rotational spindle axis. In addition, a long sample-to-detector distance (300 mm) and an oscillation of 0.5° were used to reduce overlaps. The strategy function in iMosflm 44 was used to reduce overlap as well as to maximize data completeness. Five of the six diffraction data sets were selected for analysis. The parameter for collection of the native UL141-TRAIL-R2 dataset at direct beam mode are as follows: crystal-to-detector distance (350 mm), exposure time for 10 sec and oscillation increment was 1°. Both data were indexed and integrated by iMosflm. The crystals of SeMet UL141-TRAIL-R2 belong to space group P212121, with unit-cell parameters a=67.74 Å, b=97.01 Å and c=140.94 Å and native UL141-TRAIL-R2 with a=67.71 Å, b=97.67 Å, c=141.31 Å.
Multi-Crystal Data Reduction—UL141-TRAIL-R2 Derivative
Each single-crystal data set was indexed and integrated by iMosflm 44. The CCP4 program (Collaborative Computational Project, Number 4) SCALA 45 was used for data scaling and merging with secondary beam correction and rotational restraints for scale and B factors. The ‘anomalous’ option in SCALA was turned on to allow the separation of Friedel mates in the merged data. For scaling, Friedel mates were not treated separately. A multicrystal dataset was produced by merging the five individual anomalous datasets in SCALA. Different sets of multi-crystal data were generated, including and excluding data from crystal C6. The C6 data proved to have appreciably stronger anomalous signal than the others. Data collection statistics for the native data, the C6 data as well as multi-crystal merged data are presented in Table 2. The strategy for multi-crystal data reduction was adapted from a prior strategy46.
Substructure Determination and Phasing—UL141-TRAIL-R2
Selenium-substructure determinations were performed with the SHELXD program package47. A resolution cutoff at 4.5 Å and an Emin cutoff at 1.4 were initially used to find Se substructures with SHELXD. Trials were made for each data set and for various merged data sets. For each case, 500 attempts were made to find the expected 20 Se sites. For those single-crystal and multicrystal data sets that did not yield successful Se-substructure determinations using SHELXD, Se substructures were obtained by running Phaser 48 in its MR-SAD mode with phases from the model (PDB coordinates for TRAIL-R2 (1D4V) and our incomplete homology model of UL141-Igdomain, data not shown). The model was only used for Se-substructure determination and was excluded from the subsequent SAD phasing. For all cases, initial SAD phases were calculated by Phaser. These initial phases were subjected to automatic density modification with solvent flattening and histogram matching as implemented in the CCP4 program DM and DM-Multi 49. An estimated solvent content of 51% was used for the density modification procedure. Map correlation coefficients (map CCs) and mean phase errors were calculated to compare the resulting experimental phases with model phases. In order to improve density, Uniqueify was used to generate Free R value and FFT to generate anomalous density map. Automated model builder ARP/wARP generated polyalanine model and Buccaneer (all of CCP4 package) together with AutoRickshaw structure solving module50 were used to extend this model by searching for TRAIL-R2 (from PDB 1D4V). The first interpretable model of UL141-TRAIL-R2 dimer was then rebuilt into CA-weighted 2Fo-Fc and Fo-Fc difference electron density maps using the program COOT 51. Final steps included the TLS procedure in REFMAC5 52 with three TLS domains (residues 80-180 of TRAIL-R2, 34-165 and 176-198 of UL141). The UL141-TRAIL-R2 structure was refined to 2.1 Å with a final Rfree of 27.4%. The quality of the model was examined with the program Molprobity53.
Surface Plasmon Resonance
After purification, the proteins were concentrated with an Amicon Centrifugal Filter Unit (Millipore, Ultracell-30K or 10K) and the buffer was exchanged against 10 mM HEPES pH 7.4, 150 mM sodium chloride and 3 mM EDTA (as Biacore running buffer). The proteins were diluted in Biacore running buffer containing 0.005% Tween 20 to appropriate concentration prior to loading. An anti-human Fc capture antibody was immobilized on a CM5 sensor chip (GE Healthcare) by amine coupling. Approximately 500-1000 response units (RU) of TRAIL-R2-Fc, TRAIL-R1-Fc, UL141-Fc and CD155-Fc were captured on sensor chip. TRAIL-R1 Fc, CD155 Fc and TRAIL-R2 Fc mutant proteins were captured on the sensor chip directly from the filtered culture supernatant. The serial dilutions of UL141 protein (0-0.5 μM), TRAIL-R2 receptor (0-1 μM), UL141-TRAIL-R2 protein complex (0-10 μM) were prepared in running buffer. The analytes were then injected in duplicates for 5 to 10 min association, while dissociation was conducted over 30 min. After each cycle, the chip was regenerated with a 30 sec injection of 2M MgCl2 at 15 μl/min and freshly coated with ligand (Fc-fusion protein). Experiments were carried out at 18° C. with a flow rate of 10 to 30 μl/min and performed in several repeats, each time with a different stock preparation (except for the experiment with TRAIL-R1, this was performed only once). As a negative control for unspecific binding, human LTβR-Fc (Lymphotoxin β receptor from TNFR family) was immobilized on the first flow-channel (it is know that UL141, TRAIL-R2, -R1 nor CD155 do not bind to LTβR). Kinetic parameters were calculated after subtracting the response to the negative control (LTβR-Fc) and next the buffer only control as a background, using a simple Langmuir 1:1 model in the BIA evaluation software version 4.1
Glycan Modeling
Three potential N-linked glycosylation sites were identified in the UL141 ectodomain. All of the possible asparagine residues (Asn117 in chain A, Asn132 in chain B, and Asn147 in both chains) carry one or two NAG (N-acetylglucosamine) residues that are clearly defined by electron density. While extra density is present also at the Asn117 (in chain B) and as well as Asn132 (in chain A), this density is not well defined, and no NAG was build in this location in crystal structure, but these sites were incorporated in modeling as they are occupied in adjacent UL141 subunit. Energy-minimized PDB coordinates were used for basic mannose containing N-linked carbohydrates (GlcNAG2-Man2) to visualize the surface accessibility on UL141.
Generation of Human TRAIL-R2-Fc Mutants
Human TRAIL-R2 Fc-fusion mutants (Table 5) were generated by site-directed mutagenesis using Quick Change II Multi-site Mutagenesis Kit (Stratagene, La Jolla, Calif., USA). Single mutations were incorporated using the Quick Change II Site-Directed Mutagenesis Kit (Stratagene, Agilent Technologies). Mutated constructs were purified with the Qiagen Miniprep Kit (Qiagen) and the presence of the mutation confirmed by sequencing. All mutants of human TRAIL-R2-Fc were expressed in Sf9 insect cells and the culture supernatant was used for SPR studies.
Cells and Virus.
Neonatal human dermal fibroblasts (NHDF) were obtained from Clonetics (San Diego, Calif.), immortalized human foreskin fibroblasts (HFF) are described (McSharry et al., 2001), and 293T cells were from the ATCC (CRL-11268). All cells were cultured in Dulbecco's modified Eagles medium (DMEM) supplemented with 10% fetal bovine serum, Pen/Strep and L-glutamine (Gibco). Insulin and bFGF (Sigma Aldrich) were added to NHDF media. Cells were verified mycoplasma negative. AD169 was acquired from the ATCC (VR-538, used p2-5), and Toledo was a kind gift from S. Starr (Philadelphia, used p12-15). Mutagenesis of FIX was performed as described (Hahn et al., 2002). MerΔUL141 generation is described (Prod'homme et al., 2010). HCMV virus was generated by BAC transfection into fibroblasts as described (Hahn et al., 2002; Stanton et al., 2010).
RNA Isolation and Analysis.
Total RNA was isolated from HCMV infected cells using TRIzol (Roche) followed by an RNeasy mini kit (Qiagen, Hilden, Germany). cDNA generation and real-time qPCR analysis is described (Schneider et al., 2008). For RACE analysis, a 5′/3′ RACE kit kit was used (Roche), and primers were UL141-5′ CCGGCGACGTG GTCTCATAA, UL141-3′ATCGCGGCAT TTTTGGGATT. The amplified products were purified by agarose gel and sequenced.
Flow Cytometry.
HCMV FIX infected six well dishes of NDHF or HFF were detached with diluted trypsin, washed in PBS and resuspended in PBS+2% FCS. Cells were incubated with 1° antibody for 20-30 min on ice, followed by anti-mouse IgG1 biotin (BD) and Streptavidin-APC (Pharmingen) if needed, and fixed with 1% paraformaldehyde. Anti-TRAIL-R1 and -R2 (HS101 and HS201, Alexis), anti-MHCI (W6/32, eBioscience) and anti CD155-PE (Biolegend) used at 5 μg/ml. Samples were acquired using a BD LSRII or FACScalibur flow cytometer and analyzed using FlowJo software (Tree Star). For Merlin infections, essentially the same methods were used, with secondary detection using anti-mouseAF647 (Molecular Probes, A-21238). Data was analysed with Accuri/CFlowPlus. UL141 transfected 293T and NHDF cells were analysed similarly, as were adenovirus transduced HFF and purified human NK cells.
Cell Death Assays.
MTT cell viability assays in HCMV infected NHDF (Benedict et al., 2001) and caspase 3/7 activation assays (Skaletskaya et al., 2001a) were performed essentially as described.
Plasmids, Adenovirus, Proteins and Transfections.
Plasmid vectors for expressing Fc-fusion proteins are described (PCR3-Fc)(Schneider, 2000). Adenovirus vectors expressing UL141 are described (Tomasec et al., 2005). Generation of TRAILR2ΔDD.GFP, TRAILR2ΔDD.RFP, CD155.RFP and MICA.GFP recombinant adenoviruses is described (Stanton et al., 2008), with modifications. Fc-fusion proteins used in ELISA and SPR were purified by protein A affinity from transfected 293T cell supernatants, except for TRAIL-R1:Fc (R&D Systems). For SPR studies, cell supernatants from SF9 cells transduced with baculovirus expressing His-tagged UL141ecto was collected after 3 at 27.5° C. (MOI=3), and purified using Ni2+-affinity chromatography followed by cation exchange chromatography using MonoS (GE Healthcare) and gelfiltration (Superdex 5200, GE Healthcare), by FPLC.
Six well dishes of 293T were transfected with 2 ug of UL141 plasmid as described (Cheung et al., 2005). One μg of UL141 plasmid was co-transfected into NHDF with 0.5 μg of the provided control GFP plasmid according to manufacturer's instructions (AMAXA).
Surface Plasmon Resonance Studies
SF9 cell purified UL141 was exchanged to Biacore running buffer, TRAIL DR Fc fusion proteins and hLTbR:Fc (neg control) were immobilized on an on an anti-human Fc capture chip, and binding was analyzed using a Biacore 3000 (GE Healthcare) essentially as described (Wang et al., 2010).
Western Blots
Cells were dissolved in NuPAGE LDS sample buffer (Invitrogen), proteins resolved on NuPAGE Novex 10% Bis-Tris gels (Invitrogen), transferred to nitrocellulose membrane (Hybond-C, GE) and membranes then treated with Antibody Extender reagent (Pierce) all according to manufacturers' instructions. The following antibodies were used to probe the membranes: TRAILR2 (R&D, AF631), CD155 (SDI) (Aoki, J B C, 1994:8431), UL141 (Tomasec et al., 2005), actin (Sigma A-2066), secondary antibodies were anti-mouse-HRP (BioRad 170-6516), anti-rabbit-HRP (BioRad 170-6515), anti-goat-HRP (SantaCruz sc-2056).
Immunofluorescence
Human fibroblasts (NPi) (Tomasec et al., 2000) were coinfected with relevant adenovirus vectors, 48 h after infection cells were fixed with 4% paraformaldehyde, stained with WGA-AF350 (Molecular Probes W11263) and imaged on Leica DMIRBE microscope with Improvision Openlab software.
NK Killing Assays
Purification of ‘bulk’ NK cells from IFNα activated human PBMC cultures has been described (Tomasec et al., 2005).
Statistical Analysis
Unless otherwise indicated, statistical significance was analysed by the Students T test, and data represent the mean±SEM.
Results
TRAIL death receptors (DRs) belong to the tumor necrosis factor receptor superfamily (TNFRSF), and can both promote apoptosis and regulate antiviral immunity. The UL141 protein of human cytomegalovirus inhibits host defenses by blocking cell surface expression of TRAIL DRs and CD155, a nectin-like Ig-fold molecule. Herein the present inventors discovered that UL141 utilizes at least two distinct binding sites to selectively engage TRAIL DRs or CD155. Binding studies revealed high affinity interaction of UL141 with both TRAIL-R2 and CD155 and low affinity with TRAIL-R1. The crystal structure of UL141 bound to TRAIL-R2 at 2.1 Å resolution revealed that UL141 forms a head-to-tail homodimer, through use of its Ig-domain, to bind two TRAIL-R2 monomers. While UL141 partially mimics the binding of TRAIL to TRAIL-R2, it utilizes its Ig-domain to facilitate non-canonical death receptor interactions, an emerging theme for the TNFRs.
Recently, the UL141 protein of HCMV has been shown to be both necessary and sufficient to inhibit cell surface expression of the TRAIL death receptors and that UL141 can bind directly to the ectodomain of TRAIL-R1 and TRAIL-R2 12. This discovery revealed an unexpected pleiotropic role of UL141 in regulating host immunity, as previously this HCMV protein was known to only target the nectin-related molecules CD155 and CD112. TRAIL, is highly expressed by activated immune effector cells and can mediated apoptosis 17-19, and UL141 restriction of TRAIL DR expression likely contributes to its role as a potent NK cell inhibitor 16. As UL141 is sufficient to restrict expression of both CD155 and the TRAIL DRs, the inventors set out to determine the relative binding affinities of UL141 for these host cell proteins. All binding partners were produced as Fc fusion proteins, with an engineered protease cleavage site allowing for the release of the individual ectodomains. The monovalent binding interactions were then analyzed by Surface Plasmon Resonance (SPR), while the Fc fusion proteins were immobilized on the sensor chip. Recombinant UL141 bound directly to TRAIL-R2-Fc and CD155-Fc (with high affinity (KD of 6 nM and 2 nM, respectively) (Table 1). Interestingly, an approximately 4-fold higher KD was found when UL141-Fc was immobilized on the chip and monomeric TRAIL-R2 was used as the analyte (without Fc), with even more pronounced differences seen in the association and dissociation rate constants (Table 1). When UL141 was used as the analyte, the dissociation from TRAILR2-Fc was 100-fold slower, suggesting UL141 is not a monomer in solution. This increased avidity is in agreement with size exclusion chromatography results showing UL141 is a noncovalently associated dimer in solution, while recombinant TRAIL-R2 is a monomer (
The complex of HCMV UL141 (residues 30-279) bound to human TRAIL-R2 (residues 58-184, both numberings start from the initial codon) was crystallized and the structure determined by single anomalous dispersion (SAD) to a resolution of 2.1 Å, using experimental phases derived from selenomethionine labeled protein expressed in Sf9 insect cells (see Methods herein) (Table 2). With the exception of several mobile loops of UL141, the entire N-terminal Ig-like β-sandwich domain and the cysteine rich domain (CRD) region of TRAIL-R2 (starting at residue 75-182) are well ordered in the final crystal structure and could be refined to a crystallographic R factor of 22.3% and an Rfree of 27.4%. The molecules form together a heterotetrameric complex, where one UL141 dimer binds two TRAIL-R2 monomers through non-crystallographic two-fold symmetry (
UL141 has no sequence similarity to any other known cellular protein. For SPR studies, the UL141 ectodomain was expressed as a thrombin-cleavable Fc fusion protein in Spodoptera frugiperda (Sf9) insect cells using the baculovirus mediated expression system. However, recombinant UL141 purified by this method gradually lost its ability to bind to TRAIL-R2 within 3 days, suggesting it was unstable in solution. As an attempt to attain stable and homogeneously glycosylated protein for structural studies, UL141 was co-expressed with TRAIL-R2 in Sf9 cells. The resulting complex was co-purified, and was found to be stable in solution for several weeks and amenable to crystallization. In agreement with biochemical analysis using size exclusion chromatography, UL141 forms a non-covalent homodimer (
The structure of TRAIL-R2 bound to its homotrimeric cellular ligand TRAIL has been reported previously (20 PDB: 1DU3; 21 PDB: 1D4V; 22 PDB: 1DOG). Each monomer of the trimeric TRAIL, binds to one TRAIL-R2 molecule, thereby leading to the trimerization and clustering of TRAIL-R2 on the cell surface, the hallmark oligomerization state thought to initiate signaling by TNFRs (
TRAIL-R2 is a monomer in solution (
In contrast to TRAIL binding to TRAIL-R2, which leads to head-to-head trimerization of the receptor, UL141 binding to TRAIL-R2 results in head-to-tail dimeric arrangement of TRAIL-R2 (
Two structures of TRAIL-R2 in complex with bound Fabs have also been determined (25 PDB: 2H9G; 26 PDB: 1ZA3), allowing the comparison of the TRAIL-R2 structure determined from multiple receptor-ligand complexes. Superimposition of all five TRAIL-R2 structures revealed structural changes within TRAIL-R2 that likely result from binding to distinct ligands (
Based on the contact residues identified in the UL141-TRAIL-R2 complex, alanine-scanning mutagenesis of TRAIL-R2 was then performed followed by SPR analysis to assess the relative binding requirements for TRAIL and UL141 (
In the UL141-TRAIL-R2 complex, unique contacts are formed involving E78 and D109 of TRAIL-R2 that form two salt-bridges with R102 of UL141 (
The central binding interface of the UL141-TRAIL-R2 complex is structurally similar to other TNF-TNFR complexes (
In addition to UL141 mimicking the electrostatic interaction of TRAIL with TRAIL-R2 through the use of binding patch 4, UL141 also mimics a ‘TNF-specific’ hydrophobic binding motif located within binding patch 5 in the central region of CRD-2 (
Patch 3 of TRAIL-R2 forms the most intensive interaction in the central to upper binding region with UL141. The contacts are maintained by CRD-3 β1β2 loop of TRAIL-R2, which interacts with a positively charged cluster of UL141 residues centered around K41, R80 and R82 of strands a and c, as well as R233 of helix X (
In contrast to the UL141 interacting residues of patch 5, no residues within patch 3 are conserved in the other three TNF-TNFR complexes (
Patch 3T is adjacent to patch 3, but exclusively contacts TRAIL (
The UL141-TRAIL-R2 complex was not deglycosylated prior to crystallization, and all three putative N-glycosylation sites of UL141 display well-ordered electron density for N-linked carbohydrates (Asn117 and Asn147 of first subunit and Asn132 and Asn147 of the second subunit contained ordered carbohydrates). Modeling experiments predict that native, high-mannose glycosylation would not shield much of the UL141 surface from solvent, leaving ample space for binding to other ligands, such as CD155, assuming that complex glycans would project further outward into solvent (
In view of the preceding data, the present inventors set out to further confirm the existence of an additional binding partner(s) for TRAIL-R. The inventors took advantage of mice that are genetically deficient for TRAIL (TRAIL-KO), allowing them to rule out any possible contribution of the known ligand for TRAIL-R2 in the experiments. As result of this approach, definitive data showing that additional binding partner(s) for TRAIL-R2 exist was obtained (
Human cytomegalovirus encodes several genes tightly linked to UL141 in the UL/b′ region that modulate host immune responses mediated by TNF-family proteins. These include UL138, which has recently been shown to promote the expression of TNFR-1, and UL144, a partial mimic of HVEM (herpesvirus entry mediator) that exclusively binds the inhibitory receptor BTLA (B- and T-lymphocyte attenuator) 33. Although it is common for herpesvirus immune modulatory proteins to have evolved to target a specific protein, or a family of host proteins, targeting diverse proteins that contain unique folds is rare. The present invention now adds the modulation of the TRAIL DRs to arsenal of UL141 immune modulatory activity, in addition to its previously known role in restricting CD155 and CD112 expression. TRAIL DRs and CD155 belong to two structurally distinct families, the classical TNF receptor superfamily and the nectin-like Ig superfamily, respectively. While the only currently known natural ligand, TRAIL, belongs to the TNF superfamily, the structural analysis provided herein shows that UL141 assumes an Ig-like fold and shows no structural homology to TRAIL. However, UL141 does mimic key TRAIL binding motifs of TRAIL to TRAIL-R2, even though the Ig-fold of UL141 is entirely different from the homotrimeric fold of TRAIL and other TNF ligands. Since UL141 and the Ig-like poliovirus receptors share no primary sequence homology, without being limited to any particular theory, it appears that UL141 may have evolved independently, mimicking the central binding motif of TRAIL in addition to an as-yet unidentified binding motif to engage CD155.
The present structural and biochemical data further reveal that the TRAIL-R2 binding site on UL141 only partially overlaps with that of the endogenous ligand TRAIL, and appears to be entirely distinct from that which interacts with CD155 (
Viral glycoprotein UL141 is now known to be required for restricting the cell surface expression of four cellular proteins, including TRAIL-R1, TRAIL-R2, CD155 and CD112. As CD155 was the first identified target of UL14116, the increased sensitivity of cells infected with a HCMVΔUL141 mutant to NK-killing was initially ascribed solely to inhibiting DNAM-1/CD226 activation, which also binds CD112 13. However, NK cells also express high levels of TRAIL when activated by interferons during viral infection 35, and it is a likely possibility that the potent NK inhibition by UL141 is due to its dual role in modulating multiple effector pathways such as DNAM-1/CD226 NK cell activation as well as TRAIL-mediated killing 12.
Viral manipulation of the immune response is typically achieved by virulence factors, which often imitate the function of a host protein by mimicking its key structural features 36,37. One possibility is that a virus first hijacks a host gene(s), and then further evolves/selects those genes for specific functions to target host immune signaling pathways 38. In this case, virulence factors and host proteins would be derived from the same origin, and differences in the structure and/or function of the viral ortholog would arise by divergent evolution. However, structural mimics can also be generated through convergent evolution 36. Although differing in evolutionary origin and three-dimensional structure 39, in this case virulence factors evolve to mimic key structural features of cellular proteins. Examples of the latter strategy, which can only be revealed through structural analysis, are fewer than those that can be identified by primary sequence similarity 37,40,41. While UL141 does not display any sequence homology to other proteins in the database, a DALI search (http://ekhidna.biocenter.helsinki.fi/dali_server), identified significant structural conservation with Ig-domain proteins, including T cell receptors, MHC molecules and immunoglobulins (500 proteins with a Z-score of 8.1-9.6 and RMSD 2.4-4.7 Å). The structural conservation is limited to the Ig-domain of UL141, while no homology found in the C-terminal domain (residues 160-246), indicating this domain adopts a unique structural fold. Interestingly, while the top hit of the DALI search corresponds to a variable TCR chain (Z=9.6, RMSD=3.1 over 50% TCR chain sequence), the second hit was the HCMV protein UL16, an immunoevasin that subverts NKG2D-mediated immune responses by retaining a select group of NKG2D ligands inside the cell36. UL16 aligns with 85% of its structure to the Ig-domain of UL141 (Z=9.4, RMSD=3.7). However, while the top two structural homologs of UL141 (TCR and UL16) both bind to Ig-domain MHC-like molecules, UL141 has also evolved to target the TNFRs, illustrating the functional versatility of the Ig-fold.
The structural and binding data presented herein is the first for a viral glycoprotein that directly binds to both a TNFR and an Ig-domain protein. Currently, the only other known example of a TNFR binding to an Ig molecule is HVEM-BTLA, which was recently structurally characterized 33. HVEM also binds the TNF-family ligand LIGHT. HVEM-BTLA interaction can lead to both inhibition of immune cells through BTLA signaling and activation through HVEM, while LIGHT binding to HVEM is thought to exclusively mediate co-stimulatory signals 42. Notably, UL144, the HVEM ortholog encoded by HCMV, has evolved to only bind BTLA and not LIGHT, and this has resulted in it being an extremely potent inhibitor of T cell activation 43. Consequently, both UL144 and UL141 have evolved to target non-canonical interactions of TNFRs with Ig-domain proteins. The structural analysis provided herein has revealed that HCMV has evolved the pleiotropic UL141 as a potent inhibitor of at least two different immune effector pathways, the TRAIL DRs and nectin-like NK cell activating ligands. The present invention provides new insights into the structural basis of the evolutionary dynamic that exists between persistent viruses and host defenses, exemplified by the promiscuous targeting of immune effector pathways by UL141.
HCMV is known to inhibit signaling by DRs belonging to the TNFR superfamily (e.g. TNFR-1 and Fas) (Baillie et al., 2003; Jarvis et al., 2006; McCormick et al., 2003; Skaletskaya et al., 2001b). However, HCMV isolates that have been passaged extensively in cultured fibroblasts (e.g. AD169 strain) can differentially alter TNFR expression due to the loss of specific immune modulatory proteins (Le et al., 2011; Montag et al., 2011). Consequently, to address whether infection with HCMV would target the TRAIL DRs, fibroblasts infected with distinct viral strains were analysed for their cell surface expression. The high-passage laboratory strain AD169 was used for infection (variant ATCC), as well as the FIX strain of HCMV (originally VR1814) which has been subjected to limited in vitro passage, and whose genome is available as an infectious clone in a bacterial artificial chromosome (BAC) (Hahn et al., 2002; Murphy et al., 2003). In contrast to AD169, FIX induced dramatic downregulation of both TRAIL DRs from the cell surface (
In addition to other defects, strain AD169 has suffered a spontaneous 15 kb deletion from the right hand end of the UL region (UL/b′) during passage in vitro (Cha et al., 1996). Consequently, a HCMV mutant generated in the FIX-BAC deleted in the majority of the UL/b′ sequence (FIXAUL/b′(Hahn et al., 2004)) was utilized to test for the ability to restrict TRAIL DR expression. The UL/b′ region contains≧21 genes that are dispensable for viral replication in fibroblasts (Gatherer et al., 2011). FIXAUL/b′ could not restrict cell surface expression of either TRAIL DR, indicating that an HCMV gene contained within this region was required for their inhibition (
Screening through the UL/b′ region, using a panel of pre-existing FIX BAC deletion mutants (Hahn et al., 2004), ruled out UL128, UL129, UL130, UL131a, UL132, UL148ad, C-orf23, C-orf25, C-orf26 in regulating the TRAIL DRs (data not shown). A FIXΔ139-141 mutant was then constructed, and when tested this mutant was incapable of inhibiting TRAIL DR expression, with TRAIL-R1 being commensurately upregulated on the cell surface similar to that seen with FIXAUL/b′ (
A high level of sequence variation is present in HCMV clinical isolates and cultured strains, although it is not evenly distributed throughout the genome, and this variability has been shown to impact immune evasion functions (Prod'homme et al., 2012). To further examine and confirm the role of UL141 in regulating TRAIL-R1 and TRAIL-R2 expression, the gene was also specifically deleted from HCMV strain Merlin using BAC technology. Consistent with previous findings, UL141 was required for downregulation of CD155 by strain Merlin, but not for inhibition of MHC-I (
Suppression of TRAIL-R2 cell surface expression by HCMV could be detected as early as 24 h post infection, yet became more marked as the infection progressed through 48 and 72 hours. In strain FIX, UL141 is encoded by a single abundant transcript initiated 213 bases upstream of the start codon and extending to 39 bases downstream of the stop codon, compatible with recent transcriptional mapping data for UL141 in strain Merlin (Gatherer et al., 2011). Consistent with the kinetics of TRAIL-R2 downregulation, strain FIX UL141 was found expressed as an early-late gene product, increasing in abundance dramatically throughout the viral replication cycle
The inventors have previously shown that UL141 restricts the cell surface expression of CD155 and CD112, two NK cell activating ligands belonging to the nectin/nectin-like family of proteins. Notably, the mechanisms by which UL141 modulates these two host cell proteins are quite distinct. UL141 sequesters CD155 in the endoplasmic reticulum (ER) of HCMV-infected cells (Tomasec et al., 2005), yet promotes the proteasomedependent degradation of CD112 (Prod'homme et al., 2010). To gain insight into what mechanism(s)-of-action may be utilized by UL141 to target TRAIL-R2, strain Merlin infected fibroblasts were analyzed by western blot. Notably, fibroblasts infected with Merlin showed demonstrably higher total cellular levels of TRAIL-R2 when compared to uninfected cells, or cells infected with MerΔUL141 (
Studies with HCMV deletion mutants clearly demonstrated that UL141 was required to provide efficient downregulation of the TRAIL DRs at the cell surface by both the FIX and Merlin strains. UL141 alone is sufficient to restrict CD155 cell surface expression (Tomasec et al., 2005), but additional HCMV-encoded functions were needed to target CD112 (Prod'homme et al., 2010). It was therefore sought to determine whether UL141 was able to target TRAIL DRs when expressed in isolation. A UL141 expression plasmid was transfected into both primary fibroblasts and 293T cells, and significant downregulation of TRAIL-R1 and -R2 was observed, proving that UL141 alone is sufficient to suppress TRAIL DR expression (
UL141 is a type I transmembrane glycoprotein with a short C-terminal cytoplasmic domain, and structural algorithms predict it contains an immunoglobulin-like fold in its ectodomain (Tomasec et al., 2005). To determine whether UL141 targets the TRAIL DRs by directly binding to them, the UL141 ectodomain (UL141ecto) was expressed and purified as well as a fusion protein of the ectodomain with the Fc region of human IgG1 (UL141:Fc). The binding assay demonstrated an interaction between UL141:Fc and both TRAIL-R1:Fc and TRAIL-R2:Fc. While UL141:Fc binds to the surface of human fibroblasts and 293T cells (data not shown), this result was not informative as CD155 is also expressed at high levels on most human cells. In contrast, UL141:Fc was incapable of binding to mouse NIH-3T3 fibroblasts (which express mTRAIL-R2), but transfection of hTRAIL-R2 into NIH 3T3 cells promoted strong binding of UL141:Fc, formally showing that UL141 can interact with cell-surface-expressed hTRAIL-R2. Consistent with this result, binding was not observed between mouse TRAIL-R2:Fc and UL141:Fc in an ELISA-based assay (data not shown). Taken together, both of these approaches show that UL141 binds directly to both of the human TRAIL DRs.
In order to determine the binding kinetics/affinity of UL141 for the TRAIL DRs, surface plasmon resonance analysis of UL141ecto binding to TRAIL-R1 and -R2:Fc proteins was conducted (
The fact that UL141 interacts directly with the TRAIL DRs is interesting, as UL141 shows no primary-sequence or predicted structural homology to any TNF-family ligands (Bodmer et al., 2002). This raised the possibility that UL141 might interact with additional members of the TNFR superfamily. To test this, UL141:Fc protein was used to stain 293T cells transfected with all the known TNFRs, and both positive and negative controls were included to verify that the TNFRs were expressed and functionally capable of binding their cognate TNF-family ligands (Bossen et al., 2006). In this assay format, binding of UL141:Fc (˜5 μg/ml) was only detected to 293T cells transfected with TRAIL-R2, which strongly bound the HCMV protein. Notably, binding of UL141:Fc under these conditions was not detected to 293T cells transfected with TRAIL-R1, most likely due to the relatively low binding affinity for this DR compared to TRAIL-R2, as demonstrated by our SPR analysis. Consequently, these data indicate that TRAIL-R2 appears to be the only member of the TNFR superfamily that is a specific, high affinity target for UL141.
Expression of TRAIL DRs is localized in large part to intracellular membrane compartments in lung and melanoma-derived cell lines, with a minority of the total protein localized to the plasma membrane at steady state (Leithner et al., 2009; Zhang et al., 2000). Virtually nothing is known regarding the mechanisms that regulate the trafficking of TRAIL DRs through various cellular compartments, although ER stress has been shown to upregulate TRAIL-R2 cell surface levels and sensitize them to TRAIL induced killing (Chen et al., 2007). To examine whether UL141 alters the subcellular localization of TRAIL-R2, fibroblasts were transduced with adenoviral recombinants (RAd) encoding UL141 and TRAIL-R2 constructs fused to C-terminal GFP or RFP tags and lacking an intact death domain (averting apoptosis mediated by overexpression of full-length TRAIL-R2) (e.g. RAd-TRAILR2.GFP)(
The present inventors sought to investigate whether the intracellular sequestration of TRAIL-R2 by UL141 desensitized cells to TRAIL-mediated apoptosis. To test this, human fibroblasts transduced with UL141 were treated with soluble TRAIL (
Next, the effect that UL141 restriction of TRAIL DR cell surface expression had on altering the sensitivity of HCMV infected cells to TRAIL killing was analyzed (
Lung epithelial cells expressing UL141 exhibited a marked reduction in cell surface expression of TRAIL-R2 and CD155, while intracellular levels of both molecules increased (
Herein is provided the first description of a herpesvirus gene that acts to inhibit TRAIL mediated apoptosis by specifically targeting expression of the TRAIL DRs. This study highlights the fundamental role that signaling by TNF-family cytokines plays in driving the evolution of host-attack and viral-retort that is critical for the success of persistent viral pathogens. The data is consistent with a model where gpUL141 binds directly to the ectodomain of the human TRAIL DRs in the lumen of the ER, sequestering them as a stable complex as both proteins accumulate. Consequently, transport through the Golgi apparatus and onward is impeded, and cells are desensitized to TRAIL killing. Notably, HCMV infection had previously been reported to sensitize cells to TRAIL and induce DR expression (Sedger et al., 1999), but this can now be explained by the use of the high-passage AD169 strain in those studies, which encodes a defective UL36 in combination with lacking the entire UL/b′ genomic region (Skaletskaya et al., 2001a) Cha et al., 1997). TRAIL expression is upregulated on the surface of HCMV infected dendritic cells (DC), promoting the death of virus-specific T cells that encounter them (Raftery et al., 2001). Perhaps the restriction of TRAIL DRs by UL141 is necessary to protect the infected DCs from TRAIL-mediated fratricide and/or suicide. TRAIL mRNA is also highly induced by HCMV in placental fibroblasts via the action of type I IFN (Andrews et al., 2007), suggesting a similar mechanism could be operable to thwart host immunity during congenital infection (Nigro and Adler, 2010). Consequently, HCMV may utilize the immune-suppressive activities of TRAIL to its advantage, while commensurately inhibiting its action in infected cells via the action of UL141. Intriguingly, and indicative of a multifaceted role for the TRAIL DR in CMV defense, dendritic cells from TRAIL-R2−/− mice produce increased levels of inflammatory cytokines when infected with mouse CMV (MCMV), promoting increased NK cell activation and enhanced control of viral replication in the spleen, but not the liver (Diehl et al., 2004). Although the mechanism(s) for this inhibitory role of TRAIL DR signalling in mice is not currently understood, it illustrates the importance of considering cell-type and tissue-specific roles for the TRAIL cytokine system in regulating antiviral immune defenses.
HCMV now joins a select set of viruses with predicted or demonstrated capacity to restrict TRAIL-mediated killing, with UL141 being the first herpesvirus gene shown to specifically target the TRAIL DRs. A complex encoded by the adenovirus type 2 E3 gene region (E3 6.7K/10.4K/14.5K) redirects TRAIL DR for lysosomal degradation (Benedict et al., 2001; Lichtenstein et al., 2004) and the HBV core protein inhibits TRAIL-R2 transcription (Du et al., 2009). A number of viruses preferentially target steps downstream of the TRAIL DR; indeed HCMV UL36 is an inhibitor of caspase-8. HIV infected macrophages and dendritic cells (DC) also show reduced sensitivity to TRAIL, commensurate with inhibition of TRAIL-R1 expression and increased levels of the prosurvival proteins FLIP and IAP-2 (Melki et al., 2010; Swingler et al., 2007). Cowpox and HPV-16 block TRAIL killing by altering formation of the death-inducing signalling complex (DISC) (Kabsch and Alonso, 2002; Marsters et al., 1996). In other herpesviruses, HHV-7 blocks TRAIL-R1 expression and TRAIL killing of CD4 T cells, albeit via an unknown mechanism (Secchiero et al., 2001). Kaposi's sarcoma associated herpesvirus (KSHV/HHV-8) encodes an orthologue of the cellular FLIP proteins (vFLIP) (Thome et al., 1997), competing for DISC assembly to inhibit TRAIL signaling. In latently infected B cells, Epstein Barr virus (EBV/HHV-4) restricts TRAIL killing by inducing higher NFκB-inducing via latent membrane protein-1 (Snow et al., 2006), perhaps helping to promote EBV-associated tumors (Li et al., 2011). Similar to HCMV UL36, the ribonucleotide reductase R1 subunits of herpes simplex virus types 1 and 2 binds caspase-8 to block its activation by TNFα and FasL (Dufour et al., 2011a; Dufour et al., 2011b), with TRAIL yet to be tested. Taken together, viral blockade of TRAIL-mediated apoptosis is likely to be of paramount importance given the wide swath of strategies that have evolved to inhibit it.
Although CD155 and CD112 share homology, as do TRAIL-R1 and -R2, these proteins show no primary sequence or predicted structural homology to each other. Consequently, whether UL141 utilizes a similar mechanism to bind to both the TRAIL DRs and CD155 remains an open question, and understanding the structural determinants for these interactions may shed light upon how these receptor/ligand systems function in the host. Until quite recently, interacting partners for the TNFRs were thought to be restricted to the trimeric TNF-family ligands. However, when HVEM/TNFRSF14 was found to bind the inhibitory cosignaling receptor BTLA this dogma was reassessed (Sedy et al., 2005). Interestingly, HCMV UL144 also targets this signaling system. UL144 is a partial functional-orthologue of HVEM that binds to BTLA, but not to LIGHT, and potently inhibits T cell proliferation (Cheung et al., 2005; Sedy et al., 2008). Our data highlight UL141 as the first non-TNF family protein that can interact with the ectodomain of the TRAIL DRs, providing further evidence for TNFR binding partners that extend outside of the canonical family. This interaction is highly specific, as high affinity binding of UL141 was not detected to any other member of the TNFR superfamily. It is intriguing that UL141 binds to TRAIL-R1 with a much lower affinity than to TRAIL-R2, as this exactly mimics what is seen for TRAIL binding (Truneh et al., 2000), and suggests that low affinity binding to TRAIL-R1 may have some biological significance that is currently underappreciated. Along these lines, TRAIL-R2 is normally expressed intracellularly at high abundance in uninfected cells, with UL141 greatly enhancing these levels. The UL141-mediated accumulation of TRAIL DR, as well as CD155, raises the exciting possibility that these host-cell proteins may have yet-to-be described roles as intracellular signalers, as well as potential regulators of viral persistence.
UL141 is now known to be required for restricting the cell surface expression of at least four cellular proteins, TRAIL-R1, -R2, CD155 and CD112. CD155 was the first identified target of UL141 (Tomasec et al., 2005), and the decreased sensitivity of cells expressing UL141 to NK killing is ascribed in part to its inhibition of NK activation via DNAM 1. DNAM 1 is an activating receptor that is a key initial component of NK activation/licensing to kill its target. Killing itself can then be mediated through cytotoxic granule release in conjunction with signaling by TNF-family ligands that bind to cognate death receptors. In order to assess whether UL141 restriction of TRAIL DR expression contributes to NK inhibition, a physiologically relevant assay was developed where IFNα-activated NK cells were used as effectors. Interestingly, although CD56hiNK cells only compose a small percentage of circulating NK cells in peripheral blood (˜5%), these cells express high levels of TRAIL. Consequently, since many more NK cells present in human tissues are CD56hi (Poli et al., 2009), this suggests that our assays with NK isolated from blood may even underrepresent the contribution of TRAIL in NK control of HCMV. Also, it is important to distinguish the distinct roles played by DNAM-1 and TRAIL in NK killing. DNAM-1 is involved in the 1° ‘decision-making’ process, while TRAIL participates in executing that decision. This is highlighted by the fact that in our assays, antibody blockade of DNAM-1 would not affect the negative signal mediated by CD155 binding to its ‘paired’ NK inhibitory receptor, TIGIT (Yu et al., 2009). In total, UL141 imposes a multi-layered strategy to inhibit NK cells through dampening both their initial activation and downstream killing.
Finally, targeting of TRAIL DRs, TNFR-1 and HVEM by the UL138-144 UL/b′ locus now defines this gene cluster as being highly focused on modulating signaling by the TNFR superfamily. Additionally, UL141 and UL142 (Ashiru et al., 2009) stand out within this cluster as having proven NK-modulating functions. As NK cells also express BTLA, perhaps UL144 will soon join their ranks Notably, UL141 and UL144 are also conserved and immediately adjacent orfs in the rhesus CMV genome (Hansen et al., 2003), further emphasizing their likely importance in CMV-modulation of
a)Samples with low analyte concentrations did not reach chemical equilibrium (plateau phase) during injection, which is required to perform a reliable steady-state analysis (KDeq).
b)Average equilibrium binding affinity (KDave) was derived from both KDeq and KD.
c)values from ref. 12.
primate innate immunity.
a[outer shell]
This application claims the benefit of priority to provisional application Ser. No. 61/721,368, filed Nov. 1, 2011, which is expressly incorporated herein by reference in its entirety.
| Number | Date | Country | |
|---|---|---|---|
| 61721368 | Nov 2012 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 14069030 | Oct 2013 | US |
| Child | 15151391 | US |
